Trading Analysis Report: NKE¶

Analysis date: 2026-10-21
Rating: Underweight
Generated: 2026-10-21 13:13:48
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 37.42 Price As Of: 2026-10-21

NKE (NIKE, Inc., NYSE): technical report¶

Data discrepancy: The raw price feed shows the 2026-10-21 bar as close 37.41 on volume 13,474,374. The verified snapshot shows close 37.42 on volume 13,478,030. I used the snapshot as the source of truth. The latest bar's volume is also the lowest in the 30-session window, so this bar may still be forming and could change. The supertrend, z-score and TD-9 readings are computed from OHLCV and might use the 37.41 print. The differences are immaterial, but I'm flagging them.

Indicators chosen (8) and why¶

supertrend: gives trend direction and stop levels on weekly, monthly and daily bars.
close_50_sma: medium-term trend and a dynamic reference level. The 200 SMA comes from the snapshot.
macd: momentum shifts. The signal and histogram come from the snapshot.
rsi: overbought/oversold read after a sharp rebound.
atr: volatility, for stop distance and position sizing.
obv: checks whether volume confirms the rally.
z_score: how stretched price is, on three timeframes.
td_9: exhaustion counts on three timeframes.

I skipped StochRSI and KDJ because they overlap with RSI. I also skipped separate Bollinger calls, since the snapshot already has the bands.

1. Big picture: a persistent downtrend¶

Over the 252-session window, NKE fell from a 66.18 close on 2025-10-21 to 37.42, about 43% lower. The window's closing high was 67.46 on 2025-10-23. The intraday low was 31.97 on 2026-10-02.
Monthly closing highs have stepped down in sequence: 64.59 (Jan), 63.92 (Feb), 46.46 (May), 45.48 (Jun), 44.10 (Jul), 42.19 (Aug), 38.77 (Sep) and 37.88 (Oct so far).
The 200 SMA is 46.27, about 19% above price. The 50 SMA is 37.18, well below the 200, which is a bearish long-term structure.
The 50 SMA is still falling, from 39.97 on 09-21 to 37.18 on 10-21, though the daily decline has slowed.
Several large high-volume gap days drove the slide:
2025-12-19: about -10.5% on 108.7M shares.
2026-04-01: about -15.5% on 114.2M.
2026-07-01: about +4.9% on 80.2M, after 73.9M the day before.
2026-10-01 and 10-02: 112.4M and 142.7M shares. The 10-02 bar opened at 32.55 and closed at 33.87.
These events are roughly quarterly. My tools don't establish the cause, so a news or fundamentals check should confirm whether they are earnings reactions.

2. Multi-timeframe trend (supertrend, weekly > monthly > daily)¶

Weekly: DOWN. The stop is 42.88, and the close is 12.75% below it. Price would need to rise roughly 14.6% to reach it.
Monthly: DOWN. The stop is 60.64, and the close is 38.30% below it.
Daily: UP. The stop is 34.47, and the close is 8.54% above it.
The higher tiers carry more weight, so the daily uptrend is a counter-trend bounce inside a weekly and monthly downtrend.

3. The rebound since the 10-02 low¶

Price is up about 10.5% from the 10-02 close of 33.87. The highest close since 09-08 (38.10) was 37.88 on 10-20.
The close of 37.42 is just above the 50 SMA (37.18, +0.65%) and the 10 EMA (36.56, +2.4%).
It is the first close above the 50 SMA in the 30-day window shown, reclaimed on 10-20 after closes below it on 10-15, 10-16 and 10-19.
Bollinger bands are 33.30 (lower), 35.68 (middle) and 38.05 (upper). Price is about 1.7% below the upper band.

4. Momentum¶

MACD: The line moved from -1.13 on 10-05 to +0.06 on 10-21, a fresh zero-line cross. The signal is -0.41 and the histogram is +0.46, so momentum is clearly positive.
RSI: It is 58.61 now, after a 63.19 peak on 10-20 and an oversold 28.49 on 10-02. It has room before 70, so it isn't overbought.
This is a sharp swing from oversold, but still a bounce from a deeply depressed level.

5. Volume (OBV)¶

OBV is -1.60B, up from the 10-02 trough of -1.719B but well below -1.313B on 09-21.
Price is higher than on 09-21 (37.42 vs 36.10), but OBV is lower. Volume is not confirming the rally.
That is a cautionary divergence. The 10-15 jump (+5.2% on 46.4M shares) did add volume support.

6. Exhaustion and stretch¶

TD-9: The daily count is -9, a completed sell setup, which is a short-term rally-exhaustion watch. The weekly count is -2, an early sell setup. The monthly count is +9, a completed buy setup, which is a long-horizon selling-exhaustion watch. The October monthly bar is still forming, so that reading is provisional.
Z-score: Weekly is -0.67 (near the mean), monthly is -1.42 (below the mean) and daily is +1.47 (moderately above the mean). No timeframe reaches |z| ≥ 2, so none is statistically stretched.
The signals conflict. The daily sell-setup 9 points to a pullback or consolidation. The monthly buy-setup 9 hints that the larger decline may be maturing. The weekly tier, which carries the most weight, is still in a downtrend with a small sell-setup count.

7. Volatility and risk sizing¶

ATR is 1.06, about 2.8% of price. It rose from about 0.96–0.99 in late September to 1.15 in early October and has eased since.
One ATR is about $1.06 and two ATRs about $2.12. The daily supertrend stop at 34.47 is roughly 2.8 ATRs below price.

8. Scenario map (reference levels from indicators, not validated support or resistance)¶

Constructive: The signals would improve if price closes above the 38.05 upper band and the 38.77 September closing high, with OBV turning up. After that, the weekly supertrend at 42.88 and the 200 SMA at 46.27 are the next larger hurdles.
Cautious: The daily TD-9 of -9 and the OBV divergence argue for a pullback. Levels to watch are the 10 EMA (36.56), the 50 SMA (37.18) and the Bollinger middle (35.68). A close through the daily supertrend at 34.47 would flip the daily trend down and put all three timeframes in agreement again. After that come the lower band at 33.30 and the 31.97 swing low.
Other: The data shows a $0.41 dividend on 2025-12-01, 2026-03-02, 2026-06-01 and 2026-09-01.

Summary table¶

Item	Reading	Interpretation
Close (verified)	37.42 (2026-10-21)	The raw feed shows 37.41. The bar may be incomplete.
Weekly supertrend	DOWN, stop 42.88 (close -12.75%)	Primary trend is bearish.
Monthly supertrend	DOWN, stop 60.64 (close -38.30%)	Long-term regime is bearish.
Daily supertrend	UP, stop 34.47 (close +8.54%)	Counter-trend bounce.
50 SMA / 200 SMA	37.18 / 46.27	Price is just above the 50 and about 19% below the 200. The 50 is still falling.
10 EMA	36.56	Price is +2.4% above.
MACD / signal / hist	0.06 / -0.41 / +0.46	Fresh zero-line cross with positive momentum.
RSI	58.61 (peak 63.19 on 10-20; low 28.49 on 10-02)	Recovered from oversold, not overbought.
Bollinger (L / M / U)	33.30 / 35.68 / 38.05	Price is in the upper half, about 1.7% below the upper band.
ATR	1.06 (about 2.8% of price)	Sizing and stop reference.
OBV	-1.60B (vs -1.313B on 09-21)	Volume is not confirming the rally.
Z-score (W / M / D)	-0.67 / -1.42 / +1.47	No timeframe is stretched at ±2.
TD-9 (W / M / D)	-2 / +9 / -9	Daily rally exhaustion, monthly selling exhaustion (provisional), weekly early.
Event volume	12-19, 04-01, 07-01 and 10-01/02	Recurring high-volume gaps. Cause not confirmed by my tools.
Net technical read	Structurally bearish, tactically improving	The higher-timeframe downtrend is intact. The short-term bounce is not confirmed by volume.

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 5.2/10) Confidence: Medium

Scope and data limits. Window is 2026-10-14 to 2026-10-21 for NKE (NIKE, Inc., NYSE). News: 19 Yahoo Finance headlines with titles and sources only, no article bodies, so conclusions rest on headline framing. StockTwits: 30 most-recent messages, all dated 2026-10-21 (12:10Z to 18:59Z), so this is a single-day intraday snapshot rather than a weekly read. Only 15 of the 30 carry a user sentiment label. Reddit was disabled by config, so there is no Reddit evidence and nothing can be said about r/wallstreetbets, r/stocks or r/investing. Confidence is therefore medium.

1. Source-by-source breakdown

News (institutional framing): cautious to bearish-leaning, with a rebound caveat. Roughly 7 of the 19 headlines are negative for NKE, about 4 are mildly constructive, and the rest are neutral, peer/macro or off-topic. - Negative on fundamentals and competition: 'Adidas' record Q3 is salt in the wound for Nike' (Retail Dive) frames a competitor taking share. 'How Nike's China Woes Are Putting Pressure on the Broader Market' (Footwear News) flags China weakness. 'Teen spending up 6% as they trade athletic apparel for fashion' (Retail Dive) points to a category-level demand shift away from athletic apparel. - Negative on turnaround execution and valuation history: 'Nike (NKE) Restructuring And Layoffs Put Pressure On Turnaround And Portfolio Reset' (Simply Wall St.). 'PayPal, Nike and Zoom top the list of market-value losers since 2021' (CFO.com). 'Why Is Nike Stock Falling, and Is It a Buying Opportunity?' (Motley Fool). Zacks ran NIKE as 'Bear of the Day' (two headlines, including the Vicor/NIKE Bull and Bear pairing). The bodies are not provided, so the drivers are not verifiable here. - Constructive or neutral: 'Nike's Stock Just Got a Nice Rebound. Its Comeback Is Far From Complete.' (Investopedia) acknowledges the bounce but caps enthusiasm. '7-Eleven drops lawsuit against Nike' removes a minor legal overhang. 'Genon Clears Nike Footwear Production Validation' is a small supply-chain/automation item. The Motley Fool dividend pieces (Nike yields more than P&G and about twice Coca-Cola; Nike vs. P&G) imply a depressed price and a higher yield, which is a valuation-support angle rather than a growth signal. - Read-across and macro: 'lululemon's Americas Sales Slump Deepens Turnaround Concerns' (Zacks) is a negative sector read-across. 'Inflation Is Back. Is A Stock Market Crash Next?' and 'Which Stocks Are Paying For $4.33 Gas?' (Trefis) are a macro headwind for discretionary spending. The DICK'S digital strategy piece and the Capital Group/Amazon item are neutral or irrelevant.

StockTwits (retail, fast signal): strongly bullish by label, with a thin labeled base. Of 30 messages, 14 are Bullish (47%), 1 is Bearish (3%) and 15 are unlabeled. Among labeled posts that is 14 of 15, about 93% bullish, which is at or above the 90/10 level where over-extension and contrarian risk warrant caution. The sole Bearish tag (@als3t) is a joke about Netflix and Nike merging into 'Niflix' (ticker $OOF), so it carries little analytical content. The labeled sample is only 15 posts, so the ratio is statistically fragile. - Price-action chatter dominates: 'another 10%+ ripper within just days', 'Bounce back to green! 40 USD is very close!', '40 USD this week', 'Bull run still alive as long as we above the 50 DMA', 'it's clearly on a uptrend now', 'Shorts can't make this red'. Implied levels are about $36.50-$40, with upside talk of $50 and support talk around $36.90-$38. - Some of the unlabeled posts lean cautious or bearish: @iambaron expects a drop 'back down to $36.90', @HowDidThatGetInThere says '$15 by next year', and @TriadDynamics hopes for a '36.5 btd for $39'. Unlabeled does not mean neutral. Several are tactical dip-buy plans that assume near-term volatility. - Behavior signals: 'bought more averaged down' and 'Add 200 shares' show retail adding into the rally. 'a lot of shorting again, ppl r going all in' indicates active short interest or at least retail perception of it.

Reddit: Not available (disabled by config). No inference is made.

2. Cross-source divergences and alignments - Main divergence: news flow is cautious (competitive pressure from Adidas, China, teen spending shift, layoffs, Zacks Bear of the Day, long-run value destruction), while retail is nearly uniformly bullish on a short-term rebound of roughly 10%+ over recent days. Retail appears to be leaning into a recovery and a catalyst narrative that the headlines treat as incomplete ('far from complete'). - Partial alignment: both sources acknowledge the rebound. Investopedia's 'nice rebound' matches retail's price-chasing tone. Both reference NKE being cheap, via dividend-yield framing in the news and 'a true bargain at this level' on StockTwits. - Cautionary use of NKE as a reference: several posts cite NKE as a cautionary or failed comparison ('$NFLX The next $NKE RIP', '$CMG... vibes are bad. Seen it with $NKE', '$NFLX $NKE stay broke'). This shows the market still associates NKE with a prior sharp drawdown, in line with the CFO.com market-value-loser headline.

3. Dominant narrative themes - Turnaround: 'Turnaround confirmed!', 'finally got its cost restructuring in order', a claimed '$2.5 billion savings next year' and product-momentum claims (a Caitlyn 1 shoe 'sold out', '5,000 retail locations', strong in China). These are unverified retail assertions, and the news explicitly flags China woes, so the China claim conflicts with institutional framing. - Competition and category shift: Adidas's record Q3, lululemon's weakness and teens moving to fashion. - Dip-buy/valuation: dividend yield above P&G, 'bargain', averaging down. - Technicals: 50-DMA support, $39/$40 targets, $36.50-$36.90 pullback levels. - Macro: inflation and high gas prices as a consumer-spending risk.

4. Catalysts and risks - Catalysts: an investor conference is referenced (@TimeMachine2, linking a Seeking Alpha piece, 'Nike: the catalyst we've been waiting for'). The date and content are not confirmed in this evidence. Others are restructuring savings (claimed), product launches and sell-outs (claimed), the 7-Eleven lawsuit dismissal, and possible short covering given the retail chatter about heavy shorting. - Risks: competitor share gains (Adidas), China softness, a category shift toward fashion, layoffs and execution risk, the lululemon read-across, macro inflation and fuel costs, and a lawsuit referenced on StockTwits (Ma v. Nike, a CEMA email class action at the lawsuit stage, with nothing to claim yet). Retail one-sidedness (about 93% bullish among labeled posts) after a sharp short-term run raises pullback and contrarian risk, and some posters already anticipate a retest of about $36.50-$36.90. - Evidence gaps: no earnings date, no price or volume data, no article bodies, and no Reddit data. Retail claims about savings, sell-outs and China were not corroborated by the news set.

5. Summary table

Signal	Direction	Source	Supporting evidence
Labeled retail sentiment	Bullish (contrarian risk)	StockTwits	14 Bullish (47%), 1 Bearish (3%), 15 unlabeled of 30; about 93% bullish among labeled; the only Bearish tag is a joke post
Short-term price momentum	Bullish	StockTwits	'10%+ ripper within just days', above 50 DMA, '$40 this week'; support talk at $36.50-$36.90
Insider/dip-buying behavior	Bullish	StockTwits	'bought more averaged down', 'Add 200 shares', 'took starter long term position'
Unlabeled cautious posts	Mildly Bearish	StockTwits	'back down to $36.90', '$15 by next year', hoping for a '36.5 btd'
Competitive pressure	Bearish	News	'Adidas' record Q3 is salt in the wound for Nike'; lululemon Americas slump
China exposure	Bearish	News	'How Nike's China Woes Are Putting Pressure on the Broader Market' (contradicted by an unverified retail claim of strong China sales)
Category demand shift	Mildly Bearish	News	'Teen spending up 6% as they trade athletic apparel for fashion'
Turnaround execution	Mixed	News + StockTwits	Layoffs/restructuring headline and Zacks Bear of the Day vs. claimed $2.5B savings and 'turnaround confirmed'
Valuation/income	Mildly Bullish	News	Dividend yield above P&G and about twice Coca-Cola; 'Is it a buying opportunity?'
Rebound quality	Mixed	News	Investopedia: 'nice rebound... comeback far from complete'
Legal overhang	Mildly Bullish	News	7-Eleven drops lawsuit; a new CEMA class action is only at the filing stage
Upcoming catalyst	Bullish (unconfirmed)	StockTwits	Investor conference mention; date and details not verified
Macro backdrop	Mildly Bearish	News	Inflation back; $4.33 gas pressuring consumer stocks
Reddit	No data	Reddit	Disabled by config

Bottom line for the trader: Sources point in different directions. Retail is strongly and almost uniformly bullish on a short-term rebound, while institutional news flow stays cautious on competition, China, category shift and turnaround execution. The overall read is Mixed with a roughly neutral score. The retail side is a small, one-day, thinly labeled sample, and news bodies and Reddit were not available. Treat this as a sentiment input to weigh against fundamentals and technicals, not as a price call.

News Analyst¶

NKE (NIKE, Inc.) – News and Macro Report, week of 2026-10-14 to 2026-10-21¶

1. Data coverage and limits¶

FRED macro data failed. Every macro call returned DATA_UNAVAILABLE. That covers fed funds, CPI, core PCE, 10-year yield, yield curve, unemployment and VIX. I have no current readings for these and have not estimated any. Any macro statement below comes only from news headlines or prediction markets.
News items are headlines only. The feed gave titles and sources, with no article text, so I have no figures for NKE's latest earnings, guidance, price level or analyst targets. Where I interpret a headline, I say so.
The Polymarket "Nike" search was irrelevant. It returned the Slovak Niké Liga football league, which has no connection to NIKE, Inc. I ignored it. No equity-specific prediction markets exist for NKE.

2. Company news for NKE¶

The tone is mostly negative, with some signs of stabilisation.

Negative or cautionary - Competitor strength: Retail Dive ran "Adidas' record Q3 is salt in the wound for Nike." A direct rival posting record results while Nike works through a turnaround suggests share loss or weaker execution. This is the most important competitive data point of the week. - China: Footwear News ran "How Nike's China Woes Are Putting Pressure on the Broader Market." China remains a drag on Nike, and the headline suggests it is large enough to affect sentiment beyond NKE. - Category shift: Retail Dive reported teen spending up 6% as teens "trade athletic apparel for fashion." This is a demand-mix headwind for athletic brands, though overall teen spending is rising. - Analyst sentiment: Zacks named NKE its "Bear of the Day." That label usually reflects falling earnings estimates and a poor Zacks Rank. This is my inference, and I haven't seen the article. Motley Fool also ran "Why Is Nike Stock Falling, and Is It a Buying Opportunity?" - Restructuring: Simply Wall St. ran "Restructuring And Layoffs Put Pressure On Turnaround And Portfolio Reset." Cost cuts and layoffs may support margins later but add execution risk now. - Long-term value destruction: CFO.com listed Nike among the biggest market-value losers since 2021, alongside PayPal and Zoom. This frames NKE as a long-running underperformer. - Peer read-through: Zacks reported that lululemon's Americas sales slump is deepening. That points to weakness in premium North American athletic and athleisure demand, not only at Nike.

Positive or stabilising - Rebound: Investopedia ran "Nike's Stock Just Got a Nice Rebound. Its Comeback Is Far From Complete." The stock has bounced recently, but the framing is cautious. - Legal overhang reduced: C-Store Dive reported that 7-Eleven dropped its lawsuit against Nike. This is a small positive. - Operations: Business Wire reported that Genon cleared Nike footwear production validation and won AI automation contracts in Indonesia. This hints at supply-chain automation, but the immaterial detail leaves little trading signal. - Income angle: Motley Fool says Nike now yields more than Procter & Gamble and about twice Coca-Cola. This implies a depressed share price and a relatively high yield. I didn't retrieve the yield or price. - Valuation framing: Motley Fool ran "Nike vs. Procter & Gamble," and Trefis ran "How Has Nike's Story Changed Since Last Year?" Both point to a value or turnaround debate.

Net read: Fundamental sentiment is weak (competitor strength, China, category shift, estimate pressure), while valuation and yield arguments are drawing contrarian interest. The recent rebound is described as unfinished.

3. Macro and market backdrop¶

From headlines (unverified, no text): - Trefis ran "Inflation Is Back. Is A Stock Market Crash Next?" and "Which Stocks Are Paying For $4.33 Gas?" These suggest elevated gasoline prices and renewed inflation worries. Higher fuel costs squeeze discretionary spending, which is a risk for a consumer-discretionary name like NKE. - WSJ reported "Gold Futures Edge Up as Oil Prices Slip," so oil softened slightly on the day. - MT Newswires reported stocks rising pre-bell ahead of Meta and Tesla earnings. Tech and AI dominate global headlines (IBM, Palantir, IonQ, Rigetti), and the broader market narrative is not consumer-led.

From prediction markets (Polymarket, live):

Event	Implied probability	Volume	Note
No Fed rate cuts in 2026	97%	~$9.0M	The market sees almost no chance of further 2026 cuts.
Cuts of 6, 9, 10, 11 or 12+ in 2026	~0%	$4–5M each	Aggressive easing is priced out.
US recession by end of 2026	8%	~$2.3M	A low recession probability.
2026 inflation above 4.5%	16%	~$232K	Tail risk, 1-week change −0.5pp.
2026 inflation above 5%	8%	~$342K
2026 inflation above 6%	3%	~$70K
US-Canada tariff-lowering deal by Oct 31	5%	~$93K
US-Canada tariff-lowering deal by Dec 31	40%	~$43K	Thin volume.
Trump raises tariffs on Canada by Oct 31	18%	~$3.7K	Very thin.
Copper cable hit with Sec. 232 tariffs by end-2026	28%	~$8.9K	Down 17pp in a week, thin.

What this means for NKE: - Rates: With a 97% chance of no 2026 cuts, there's no easing tailwind for consumer multiples. NKE has to earn any re-rating through execution. I could not check the current policy rate or the 10-year yield. - Recession: At 8%, a hard consumer downturn is not the base case, which helps discretionary demand. The inflation and gas-price headlines pull the other way. - Tariffs and sourcing: Nike makes most of its footwear in Vietnam, Indonesia and China. I found no Polymarket markets on China or Southeast Asia tariffs, and the tariff markets I did find are about Canada and copper, so I can't give a market-implied read on Nike's main sourcing risk. This is a gap.

4. Trading takeaways¶

Bias is cautious, with a contrarian floor. Competitive and estimate-revision news is negative, but the yield and valuation narrative and the recent rebound mean downside may be partly priced. I can't tell how much without price and earnings data.
Watch Adidas and other sportswear peers. Adidas's record Q3 and lululemon's Americas slump point to share shifting among brands, not a uniform category decline. Read the Adidas, On and Deckers results for North America and China trends.
China is the swing factor. Any sign of stabilisation or further deterioration in Greater China can move NKE more than macro news.
No rate relief. The 97% no-cut market and the inflation and gas headlines argue against a macro-driven rally in discretionary stocks.
Next company catalyst: Nike's fiscal Q2 report is normally in late December. That is a historical pattern, not something I verified, so confirm the date. Until then, expect headline-driven moves from peer earnings, restructuring news and China data.
Gaps to fill: NKE price and technicals, the last earnings print and guidance, the fed funds rate, CPI and PCE trend, the 10-year yield, the VIX, and tariff exposure. These need another data source.

5. Summary table¶

Category	Item	Evidence / source	Direction for NKE	Confidence
Competition	Adidas posts record Q3	Retail Dive (headline)	Bearish	Medium (no text)
Regional	China weakness weighs on Nike and the market	Footwear News (headline)	Bearish	Medium
Demand	Teens shift from athletic apparel to fashion (spending +6%)	Retail Dive (headline)	Bearish	Medium
Peer read-through	lululemon Americas sales slump deepens	Zacks (headline)	Bearish	Medium
Sentiment	Zacks "Bear of the Day" on NKE	Zacks (headline)	Bearish	Medium (inference)
Corporate	Restructuring and layoffs	Simply Wall St. (headline)	Mixed (cost savings vs. execution risk)	Medium
Long-term	Among the biggest market-value losers since 2021	CFO.com (headline)	Bearish context	High
Price action	"Nice rebound," comeback far from complete	Investopedia (headline)	Mildly positive	Low–medium
Valuation	Yield above P&G and about 2x Coca-Cola	Motley Fool (headline)	Supportive for value and income buyers	Medium (no figures)
Legal	7-Eleven drops lawsuit	C-Store Dive (headline)	Mildly positive	Medium
Operations	Genon AI automation validated in Indonesian footwear production	Business Wire	Neutral to slightly positive	Low
Rates	No Fed cuts in 2026 at 97%	Polymarket, ~$9.0M volume	No macro tailwind	High
Growth	US recession by end-2026 at 8%	Polymarket, ~$2.3M volume	Neutral to supportive	Medium–high
Inflation	2026 inflation above 4.5% at 16%; above 5% at 8%	Polymarket	Tail risk to consumer spending	Medium
Energy and prices	"Inflation is back"; $4.33 gas	Trefis (headlines)	Bearish for discretionary	Low–medium (no text)
Tariffs	US-Canada deal by Dec 31 at 40%; no China or Asia sourcing markets found	Polymarket (thin)	Unknown for NKE	Low
Macro data	FRED series (rates, CPI, PCE, 10-year yield, VIX, unemployment)	Tool failure	Not available	N/A
Catalyst	Fiscal Q2 earnings, historically late December	General pattern, unverified	Next major event	Low (confirm date)

Fundamentals Analyst¶

NKE (NIKE, Inc.) Fundamental Report, as of 2026-10-21¶

Scope note: The tools return no filings or insider transactions dated within the last 7 days. - The latest financial period is the quarter ended 2026-08-31 (fiscal Q1 FY27). - The latest insider record is 2026-09-15, 36 days ago. - This report covers the latest available data, not just the past week.

1. Company Profile and Snapshot¶

Item	Value
Company / Exchange	NIKE, Inc. / NYQ
Sector / Industry	Consumer Cyclical / Footwear & Accessories
Market cap	~$55.6B
Implied share price	~$37.4 (book value $10.263 × P/B 3.65; matches the 50-day average of $37.37)
52-week range	$31.97 – $70.44
50-day / 200-day average	$37.37 / $47.14
Beta	1.10

Price context: The stock trades about 47% below its 52-week high and about 17% above its low. It sits at its 50-day average and about 21% below its 200-day average, a persistent downtrend.

Valuation

Metric	Value	Comment
P/E (TTM)	18.0x	Treat with caution (see section 7)
Forward P/E	23.4x	Forward EPS $1.60 is below TTM EPS $2.08, so the market expects earnings to fall
PEG	1.58
P/B	3.65x
P/S (derived)	~1.2x
EV/EBITDA (derived)	~12x	Uses implied debt of ~$11.1B and cash of $6.9B
Dividend yield	4.33%	High by Nike's history, mostly because the price has fallen

Profitability (TTM, per snapshot)

Metric	Value
Revenue	$45.89B
Gross profit / margin	$19.92B / 43.4%
EBITDA	$4.89B (10.7% margin)
Operating margin	7.9%
Net income / margin	$3.09B / 6.7%
ROE / ROA	21.6% / 6.9%
Free cash flow	$1.77B

2. Income Statement Trends (quarterly, USD millions)¶

Q4 (May) quarters are not in the income statement feed, and operating income is "unavailable" in every period.

Quarter	Revenue	YoY	Gross Profit	Gross Margin	Net Income	NI YoY	Diluted EPS
Q1 FY25 (Aug-24)	11,589		5,257	45.4%	1,051		0.70
Q2 FY25 (Nov-24)	12,354		5,389	43.6%	1,163		0.78
Q3 FY25 (Feb-25)	11,269		4,675	41.5%	794		0.54
Q1 FY26 (Aug-25)	11,720	+1.1%	4,943	42.2%	727	−30.8%	0.49
Q2 FY26 (Nov-25)	12,427	+0.6%	5,045	40.6%	792	−31.9%	0.53
Q3 FY26 (Feb-26)	11,279	+0.1%	4,530	40.2%	520	−34.5%	0.35
Q1 FY27 (Aug-26)	11,213	−4.3%	4,798	42.8%	712	−2.1%	0.48

Takeaways - Revenue has turned negative again. Growth was about +1% or less for three quarters, then fell 4.3% YoY in the latest quarter. Q1 FY27 revenue is 13% below Q1 FY24 ($12.94B). - Margins are stabilizing. Gross margin was 42.8%, up about 60bps YoY. It is still about 260bps below Q1 FY25 (45.4%) and the Q3 FY26 trough (40.2%) was only two quarters ago. - The earnings decline has slowed sharply. Net income fell 31–35% YoY for three straight quarters and only 2% in the latest. This is the best year-over-year comparison in the dataset, but it comes from lower revenue, so the improvement is margin-driven rather than demand-driven. - Earnings are about half of their peak. Q1 FY27 EPS of $0.48 compares with $0.94 in Q1 FY24, down about 49%.

3. Balance Sheet (USD millions)¶

Date	Cash & Equiv.	Current Assets	Total Assets	Current Liabilities	Equity	Current Ratio
2025-08-31	7,024	23,898	37,334	10,911	13,468	2.19
2026-05-31	7,563	24,603	38,410	12,547	14,865	1.96
2026-08-31	6,903	23,673	37,794	11,409	15,220	2.08

Liquidity is solid. The current ratio of 2.08 matches the snapshot, and working capital is about $12.3B.
Leverage is moderate. Debt/equity is 0.73x. Implied total debt is about $11.1B, which likely includes leases. Net debt after cash is about $4.2B, or roughly 0.9x EBITDA. This is my derivation, since the balance sheet feed has no debt lines.
Cash fell $660M in one quarter (from $7.56B to $6.90B).
Equity is up 13% YoY to $15.2B. Book value per share is $10.26.
Data gaps: Total liabilities, inventory and debt line items were not returned.

4. Cash Flow (cash flow figures are year-to-date cumulative; USD millions)¶

Period	Operating CF	Capex	FCF (OCF − Capex)	Financing CF
Q1 FY26 (3M)	222	207	+15	−598
9M FY25	3,235	330	+2,905	−4,176
9M FY26	1,231	546	+685	−1,778
Q1 FY27 (3M)	135	199	−64	−618

Cash generation has deteriorated sharply. Nine-month operating cash flow fell 62% YoY and nine-month FCF fell about 76%. Q1 FY27 operating cash flow was down 39% YoY and FCF was negative.
Capex is running higher. Nine-month FY26 capex was up 65% YoY.
The Q1 FY27 cash decline reconciles. Operating cash flow of +135, investing of −192 and financing of −618 sum to about −675. That matches the −660 change in cash after a small FX effect.
Financing outflows look like dividends only. Outflows of about $600M per quarter approximate the dividend (about $0.40 per share on about 1.485B shares). Nine-month financing fell from −$4.2B to −$1.8B, which suggests buybacks have been largely halted. This is an inference, since the tool does not break out dividends or repurchases.

Dividend coverage (derived) - The annual dividend is about $1.62 per share, or about $2.4B in total (from yield × price). - That is about 78% of TTM net income and about 136% of TTM FCF. - It is roughly 101% of forward EPS ($1.60). - Cash of $6.9B funds the gap for now. If FCF stays weak, the dividend or the balance sheet will absorb the shortfall.

5. Insider Activity¶

Open-market purchases (a strong signal in a downtrend)

Date	Insider	Shares	Price	Value
2025-11-07	Knudstorp (Director)	16,150	$62.09	$1.00M
2025-12-22	Cook (Director)	50,000	$58.97	$2.95M
2025-12-22	Swan (Director)	8,691	$57.54	$0.50M
2025-12-29	Hill (CEO)	16,388	$61.10	$1.00M
2026-04-07	Swan (Director)	11,781	$42.44	$0.50M
2026-04-09	Rogers (Director)	4,000	$43.34	$0.17M
2026-04-10	Cook (Director)	25,000	$42.43	$1.06M
2026-04-13	Hill (CEO)	23,660 ×2	$42.26 / $42.27	$1.00M ×2

Total buying: about $9.2M. If the two 4/13 Hill lines are one duplicated filing, the total is about $8.2M.
Buyers are underwater. The December purchases at $57–61 are down about 35–39% at ~$37.4. The April purchases at ~$42–43 are down about 12%.
No open-market purchases since 2026-04-13, about 6 months. Insiders did not add on the further drop from ~$42 to ~$37.

Open-market sales since April 2026: about $1.57M, all officers, no director sales

Date	Insider	Value	Price
2026-06-12	McCartney	$803K	$46.18
2026-08-05	Four officers	$195K combined	$41.60
2026-08-07	Montagne (President)	$205K	$42.05
2026-09-09	Leinwand, McCartney, Alagirisamy	$371K combined	$37.59

The sizes are modest. The tool does not say whether they are tax-withholding or 10b5-1 sales.

Mark Parker (Executive Chairman) - He sold about $45M of stock between Nov 2024 and Nov 2025, with sales at $62–76 often paired with option exercises at $56.40. - He has made no sales since 2025-11-14, only gifts in May and August 2026.

Other events - Grants: CEO Hill received 108,400 shares on 2026-09-01, and CFO Denton 71,234. The nine directors each received 5,047 shares on 2026-09-08. That is nearly double the 2,619 shares granted in Sep 2025, consistent with a roughly fixed dollar value (~$190–200K) at a price about half as high. - CFO transition: Matthew Friend is listed as CFO through 2026-08-05, and David Denton as CFO from 2026-09-01. Verify the change via 8-K or news. - New director: Alexandre Arnault first appears with a director grant on 2026-09-15. Verify. - Gifts (non-economic): Philip Knight gifted 4.5M shares (Feb 2026), and Travis Knight gifted ~2.85M shares (Jul 2026).

6. Actionable Observations (for the decision-maker)¶

Supportive factors 1. Earnings declines have slowed from about −30% or worse to −2% YoY, and gross margin is recovering (+60bps YoY). 2. The balance sheet is sound: current ratio 2.08, $6.9B cash and moderate leverage. 3. Insiders including the CEO and board members bought about $8–9M between Nov 2025 and Apr 2026. 4. The stock is down 47% from its high, with a 4.3% yield and ROE around 21%. 5. Parker has made no sales since Nov 2025.

Risk factors 1. Revenue fell 4.3% YoY after three flat quarters, so the top line has not stabilized. 2. Cash flow is weak: nine-month FCF is down about 76%, Q1 FY27 FCF was negative, and cash fell $660M in the quarter. 3. The dividend is not covered by TTM FCF, and it is about 100% of forward EPS. Forward EPS ($1.60) is well below TTM EPS ($2.08). 4. The price is below its 200-day average, and a 52-week low of $31.97 is about 15% below the current price. 5. Insider buying has stopped since April, officers have sold modestly since June, and the CFO has changed.

Potential catalysts and what to watch - Q2 FY27 results, typically reported in late December. Watch whether revenue growth returns, whether gross margin holds near or above 42.8%, and whether operating cash flow recovers. - Any change to dividend policy or buyback status. - Whether insiders resume buying near or below $37.

7. Data Quality Caveats¶

The TTM snapshot does not reconcile with the quarterly statements. Subtracting the three known quarters from TTM implies a missing Q4 FY26 with a ~50% gross margin, ~$1.07B net income and ~$0.72 EPS. That is far outside the 40–43% margin and $0.35–0.53 EPS run-rate. The TTM P/E of 18x, ROE of 21.6% and TTM FCF may therefore be distorted. The forward P/E of 23x is probably the more realistic multiple.
Q4 quarters are missing from the income statement, operating income is unavailable, and cash flow items are cumulative.
The snapshot has no stated date, so its price and TTM figures may be stale or mismatched.
Possible duplicates in the insider data: Hill's two 4/13 purchases, and Parker's two identical 5/14/2026 gifts.

8. Summary Table¶

Category	Key Point	Reading
Valuation	P/E 18.0x TTM (suspect) / 23.4x forward; P/B 3.65x; yield 4.33%	Neutral to expensive on forward earnings
Revenue	Q1 FY27 $11.21B, −4.3% YoY after ~+1% for 3 quarters	Negative
Margins	Gross margin 42.8% (+60bps YoY, vs 45.4% two years ago); net margin 6.4%	Stabilizing, below prior levels
Earnings	EPS $0.48 vs $0.49 (−2%), after −30–35% declines	Improving rate of decline
Cash flow	Q1 FY27 OCF $135M, FCF −$64M; 9M FY26 FCF down ~76%	Negative
Dividend	~$2.4B/yr vs TTM FCF $1.77B; ~100% of forward EPS	Coverage risk
Buybacks	Financing outflows ≈ dividends only	Likely halted
Balance sheet	Cash $6.9B, current ratio 2.08, D/E 0.73x, equity $15.2B	Positive
Insider buying	~$8–9M (Nov 2025–Apr 2026), none since 4/13	Positive but stale
Insider selling	~$1.57M officer sales since Jun 2026; Parker none since Nov 2025	Mildly negative
Management	CFO changed (Friend → Denton); new director Arnault	Verify via news/8-K
Technicals	$37.4 vs 200-day $47.1; range $31.97–$70.44	Downtrend
Data quality	TTM figures conflict with quarterly data; Q4 and operating income missing	Verify before relying on TTM

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # The Bull Case for NKE: A Trough Earnings Story at a Trough Sentiment Price

I'll open by conceding that NKE is not a clean story. The weekly and monthly trends are down, revenue just slipped, and free cash flow is weak. But the stock is priced for those facts, and the data shows the earnings trajectory turning before the price has.

1. The earnings decline has nearly stopped¶

Net income fell 30.8%, 31.9% and 34.5% YoY in three straight quarters. In the latest quarter (Aug-26) it fell 2.1%, with EPS of $0.48 against $0.49. That is the inflection a turnaround investor looks for.

The margin trend supports it:

Quarter	Gross margin
Q3 FY26 (Feb-26)	40.2% (trough)
Q1 FY26 (Aug-25)	42.2%
Q1 FY27 (Aug-26)	42.8%
Q1 FY25 (Aug-24)	45.4%

Gross margin is up 60bps YoY and 260bps off the trough, and it is still 260bps below where it stood two years ago. The comps get easier from here. Q2 FY26 gross margin was 40.6%, so simply holding 42.8% in the December quarter would be about 220bps of YoY improvement.

The arithmetic is worth spelling out. Recovering the 260bps gap on roughly $45B of revenue is about $1.2B of annualized gross profit. TTM net income is $3.09B, and I'm treating that figure cautiously (more below). Quarterly EPS is about half its Q1 FY24 level ($0.94), so modest margin repair has outsized earnings leverage.

2. The balance sheet buys time¶

Cash: $6.9B.
Current ratio: 2.08.
Equity: up 13% YoY to $15.2B.
Leverage: debt/equity of 0.73x and net debt of about 0.9x EBITDA (my derivation, since the feed has no debt lines).

NKE is not a levered turnaround that needs a perfect quarter. It can fund the restructuring, absorb a soft holiday, and keep investing in product.

3. The valuation embeds a lot of pessimism¶

The stock is 47% off its 52-week high at about $37.42, with a 4.33% dividend yield, roughly 1.2x sales and about 12x EV/EBITDA. Those EBITDA and margin figures are depressed, since operating margin is 7.9% and gross margin is well below its prior range.

I'm not going to lean on the 18x TTM P/E. As the fundamentals report flags, the TTM snapshot doesn't reconcile with the quarterly data. The 23.4x forward P/E is the honest number, and it is paid on earnings at roughly half their prior run-rate. If you believe margins can recover even partway, that multiple compresses fast.

4. Insiders put real money in, including the CEO¶

From Nov 2025 to Apr 2026, directors and the CEO bought about $8–9M in open-market purchases (Cook, Swan, Knudstorp, Rogers, and CEO Hill twice). Executive Chairman Mark Parker, who sold about $45M between Nov 2024 and Nov 2025, hasn't sold since 2025-11-14. No director has sold since April, and the officer sales were small ($1.57M in total).

5. The tape shows capitulation, then a turn¶

On 10-01 and 10-02, NKE traded 112M and 143M shares. RSI hit an oversold 28.49, and the intraday low was $31.97. Since then:

Price is up about 10.5% from the 10-02 close.
It has reclaimed the 50 SMA (37.18) and sits above the 10 EMA (36.56).
MACD just crossed the zero line, with a +0.46 histogram.
RSI is 58.6, not overbought.
The daily supertrend is up, with its stop at 34.47.
The monthly TD-9 shows a completed buy setup (+9). It's provisional because October is still forming.

Where I expect the bear to push, and my answers¶

"Revenue fell 4.3% YoY. The top line hasn't stabilized." This is the best bear point and I won't dodge it. But margin expanded while revenue fell. My inference, which the data can't confirm, is that this is consistent with less promotional clearance and cost discipline, not a demand-driven bounce. Earnings leading revenue out of a trough is how most turnarounds work. If December revenue is down again, I'll have to rethink.

"FCF is down 76% over nine months, and the dividend isn't covered." The nine-month FCF decline is real. But Q1 is seasonally small. Q1 FY26 FCF was +$15M, so the Q1 FY27 figure of −$64M is a swing of about $79M, not a collapse. The dividend costs about $2.4B a year, and $6.9B of cash covers roughly three years of it even at zero FCF. The financing outflows suggest buybacks have been largely halted, so the dividend is the only call on cash. The risk is that a long stretch of weak FCF forces a choice, and I'd watch operating cash flow in the December quarter.

"The weekly and monthly supertrends are down." They are, and I'm not claiming otherwise. This is a call on risk/reward turning, not on the trend having reversed. Upside to the weekly stop (42.88) is about 15%, and to the 200 SMA (46.27) about 24%. Downside is about 8% to the daily stop (34.47) and about 15% to the swing low (31.97). That's favorable but not lopsided, which is why I'd scale in and not go all at once.

"The daily TD-9 sell setup and the OBV divergence say pullback." I agree, and a retest of the 10 EMA, the 50 SMA or the 35.68 Bollinger midline would be normal. OBV is −1.60B against −1.31B on 09-21, so volume isn't confirming the rally yet. I'd treat a pullback as an entry opportunity unless 34.47 breaks.

"The news is terrible: Adidas's record Q3, China, teens shifting to fashion, Zacks 'Bear of the Day'." Those are headlines only, with no article bodies, so I'd weigh them accordingly. Adidas posting a record quarter tells me athletic footwear demand exists. NKE's issue is execution and positioning, which is fixable, not a dying category. Sentiment this negative at multi-year lows is what contrarian entries are made of. I'm not counting the 93% bullish StockTwits ratio as support, though. It's a thin, one-day sample and a crowding risk.

"Insider buying stopped in April." True, and the buyers are underwater (about −35–39% on the December purchases and about −12% on April's). But the decision-makers who know the turnaround plan best bought twice, and the directors aren't selling.

Macro and what I can't verify¶

Prediction markets put 97% on no Fed cuts in 2026 and only 8% on a US recession. That means no rate tailwind, but also no consumer collapse. The thesis rests on NKE's execution, not on multiple expansion. I couldn't retrieve FRED data, and I found no market-implied read on tariff risk for NKE's Vietnam, Indonesia and China sourcing. That is a real gap, and I'd rather name it than guess.

Bottom line¶

NKE has a sound balance sheet, earnings declines that have slowed from about −30% to −2%, gross margin recovering off a trough, directors and the CEO buying near $42–61, and a stock that capitulated to $31.97 and is now building a base. The next test is the fiscal Q2 report, historically in late December (please confirm the date). My checklist is:

Gross margin at or above 42.8%.
Revenue decline narrowing.
Operating cash flow turning up.
No dividend change.

If those hold, the market is pricing NKE as if the trough is permanent. I'd build a position in tranches around the 36.56–37.18 support area, with 34.47 as the line that tells me I'm wrong.

I'm interested to hear which of these the bear thinks is the weakest link. Bull Analyst: # Bull Reply: I'll Take the Seasonality Correction, and the Direction Still Holds

You landed several real hits. I'll concede them first, then show what survives.

What I concede¶

Checklist item #1 was mis-set. Q1 is the high-margin quarter and steps down about 160-180bps into Q2, so "hold 42.8% in December" would be unusual. "260bps off the trough" also compared an August quarter to a February one.
I can't drop the TTM P/E and keep the TTM EV/EBITDA. I'm retiring the 12x. It's realistically 12-14x, and I won't lean on it.
A stop at 34.47 doesn't protect against gaps. Position size does.
Equity growth isn't an earnings signal. It's balance-sheet comfort.
I can't show revenue stabilization. It is my weakest link, more than cash flow.

Your seasonality correction helps me¶

Compare each quarter to the same quarter a year earlier, which removes seasonality:

Quarter	Gross margin	Same quarter prior year	YoY change
Q1 FY26	42.2%	45.4%	−320bps
Q2 FY26	40.6%	43.6%	−300bps
Q3 FY26	40.2%	41.5%	−130bps
Q1 FY27	42.8%	42.2%	+60bps

The YoY gap was −320, −300, −130, then +60. This is the first positive like-for-like margin comparison in the dataset. Your base case for December (+40-60bps) would make it two in a row after three negatives. You call that "the same modest improvement." I call it a sign change that persists.

The size is small, though. 50bps on about $12B is roughly $60M of gross profit a quarter. That's direction, not recovery.

The gross-profit math is right, but the conclusion isn't¶

Your decomposition holds: about −$214M from volume and +$69M from rate. But net income fell only $15M, so about $130M came from below the gross profit line. You call that harvesting. Neither of us can see which line it is, because operating income is "unavailable" in my feed. If it's SG&A, it's durable and consistent with the restructuring headlines. If it's tax or one-offs, it isn't.

The 10-Q for the quarter ended Aug 31 should be on file by now and will say which. I'm putting that on the checklist. If the cushion is mostly non-recurring, I cut conviction sharply.

Revenue: you're right¶

Adidas printing a record quarter while NKE falls 4.3% points to share loss. I can't rebut that. What I can say is what's priced. P/S is about 1.2x, and unlike the earnings lines, the revenue line reconciles: TTM backs out to an implied Q4 of about $10.97B, in range with the other quarters. The market is capitalizing a shrinking top line, so the stock doesn't need growth to work. It needs the decline to stop worsening. That means Q2 revenue of about $11.9B or better, which is no worse than −4.3% against a $12.43B comp.

The dividend: uncovered by FCF, but less alarming than framed¶

Earnings coverage: Q1 EPS of $0.48 against the $0.41 dividend is 1.17x. Your crude annualization ($1.81 vs $1.64) is about 1.10x. FCF doesn't cover it, and hasn't for at least four quarters. That's a risk, and it's why I'm capping size.
Cash: $6.9B is only 1.7% below $7.0B a year ago, despite the FCF collapse, because buybacks stopped. The $660M quarterly drop isn't new. FCF plus financing was about −$583M in Q1 FY26 and −$682M now, so about $100M worse (ignoring FX and other investing).
Capex: The +65% was a 9M FY26 story. Q1 FY27 capex was $199M against $207M, down 4%. The ramp has stopped.
Track record: $0.41 was paid on all four dates through three quarters of −30% earnings.
"The last lever": At zero FCF, cash covers about 2.9 years of dividends. A cut would be a choice, not a necessity, inside the Q2 window. Still, a cut is the scenario where I lose money.

Valuation: use quarterly data¶

The Street's $1.60 is below your $1.81 crude annualization. If $1.60 is a fiscal-FY27 figure (my feed doesn't say), Q1's $0.48 leaves $1.12 for three quarters, or $0.37 each. That's barely above the Q3 FY26 trough ($0.35) and well below Q2 FY26 ($0.53). It would mean the Street is modeling a re-run of the trough, which is what "priced for the facts" means.

But I have no guidance data, and that is the biggest hole in my inputs. I'd read the Q1 call transcript before adding.

The tape¶

If the 10-01/10-02 gaps were the Q1 print, which the cadence suggests but my tools don't confirm, the market sold it for two days and then bought it back. - 10-02 reversal: The bar opened at 32.55, hit a low of 31.97 and closed at 33.87 on 142.7M shares, the heaviest event day in the report. - Bounce: Price is +17% off the low and +10.5% off that close. - OBV: It is up about 119M since the 10-02 trough (−1.719B to −1.60B). The two event days alone traded 255M shares, close to the entire 287M gap versus 09-21.

I accept the daily TD-9 at −9, the falling 50 SMA and the stair-stepping monthly highs. That's why I'm not chasing. On risk/reward, your 1:1 uses a $37.42 entry and the weekly stop as the upside. From the 36.56 10 EMA, the 200 SMA (46.27) is +26.6% away against −12.5% to 31.97, about 2.1:1. From the 35.68 Bollinger midline it's better.

Sequencing: where I move toward you¶

Of the four gap events, three were down (−10.5%, −15.5%, and October), and one was +4.9%. I'll treat that as the base rate, so:

Starter: about 1% of portfolio at 36.56-37.18 or lower. A repeat of April's −15.5% gap costs about 15bps.
Main position: after the print, if the checks below pass, even at $40. I'll pay the roughly 7% premium for the information.
Final tranche: on a weekly close above 42.88.

Revised checklist (replaces mine)¶

Q2 gross margin of 41.1% or better (+50bps YoY, your own base case).
Q2 revenue of about $11.9B or better (decline no worse than −4.3%).
10-Q confirms the ~$130M cushion is SG&A, not tax or one-offs.
H1 operating cash flow ahead of H1 FY26, and the dividend unchanged.
A fresh director or CEO Form 4, or at least no director selling. My insider feed ends 9/15, so I can't say what happened after the print.

Your question, answered¶

My weakest link is revenue (#2), then operating cash flow. If Q2 revenue is worse than −4.3% and gross margin slips back below 41%, then 31.97 isn't the floor, and I'd say so.

What I'm holding onto is this: two independent lines have turned. Net income YoY went from −31% to −2%, and like-for-like gross margin YoY went from −320bps to +60bps. After a 17% bounce, the stock is still 47% below its high at 1.2x sales. That justifies a small starter now and a larger position only after the print. Bull Analyst: # Bull Final Reply: The Cushion Is a Cost Reset, and Revenue Decides Whether It Matters

You're right about the checklist and the sequencing, so I'm changing both. But "one line and a hole" has a hole in it too, and the same numbers narrow it.

What I concede¶

A status-quo print passes my old checklist. $11.9B at 41.1% is gross profit of −3.1% YoY, against −2.9% in Q1. That's a trough persisting, not turning.
Margin repair didn't produce Q1's earnings. The margin gain is worth about 3¢ a share. "Two independent lines" was really one margin line worth little and one cost line I couldn't see.
I'm withdrawing the unconditional starter. The 10-Q is available now, so reading it first costs nothing.
The insider signal is stale. It tells us what insiders thought at $42–61, not at $37.
The risk/reward is 1.6:1 from $37.42, not 2.1:1.
I can't rely on the TTM FCF figure in either direction. Forward EPS covers the dividend about 1.0x. FCF doesn't cover it.

The "hole" is narrower than "unknown"¶

The gap between gross profit and net income covers opex, interest and other items, and tax. Here is how it moved:

Quarter	Δ Gross profit	Δ Costs below GP	Δ Net income
Q1 FY26	−314	+10	−324
Q2 FY26	−344	+27	−371
Q3 FY26	−145	+129	−274
Q1 FY27	−145	−130	−15

This is the first YoY decline in below-GP costs in the dataset. It also explains the −34.5% in Q3 FY26. Gross profit fell only 3.1%, but costs rose $129M.
It isn't a base effect. Below-GP costs were $4,206M in Q1 FY25 and $4,216M in Q1 FY26, so the comp wasn't inflated. Q1 FY27 came in at $4,086M, the lowest of the three Q1s in the data. A Q3 charge rolling off can't explain it, because Q3 isn't Q1's comp.
It's about 3% of costs. That is modest, and it fits the restructuring headlines. It also includes tax and other items, so it could still be partly one-time.
It isn't operating leverage. Net income was 14.8% of gross profit, against 14.7% a year ago. Costs fell about as fast as gross profit did.

So your "harvesting" label is fair for now. My claim is narrower than "inflection": the cost base stepped down against a clean comp, and the 10-Q will say whether it's durable. A recovery needs revenue, which is your point, and I don't have a rebuttal on the data.

The checklist, rebuilt around gross profit dollars¶

Revenue needed in Q2, against $5,045M of gross profit last year:

Q2 gross margin	Revenue for GP flat	Revenue for GP −1%
41.1%	$12.28B (−1.2%)	$12.15B (−2.2%)
41.5%	$12.16B (−2.2%)	$12.04B (−3.2%)
42.0%	$12.01B (−3.3%)	$11.89B (−4.3%)

I'd set the tiers like this:

Outcome	Condition	Action
Add the main position	GP ≥ −1% YoY and EPS ≥ ~$0.50	Buy
No adds	GP between −1% and −3%	Wait
Stand aside	GP worse than −3%, EPS below $0.45, or dividend cut	No position

The EPS line tests whether the cost reset persists. If gross profit comes in at your −$154M and the $130M cost saving holds, net income is about $768M, or EPS of about $0.51. If EPS comes in near $0.45 or lower, the saving was one-time.

Your status-quo print (−3.1%) lands on the stand-aside line. I'd treat it as a no, because cost cuts can't carry a shrinking gross profit line indefinitely.

Street math¶

If the $1.60 is a post-print FY27 figure, Q2–Q4 averages $0.37. That is below Q2 FY26's $0.53, and below what my cost-persistence case implies for Q2 (about $0.51). So one of two things is true:

The consensus is stale or too low. Then 23.4x overstates the multiple and revisions are coming.
It embeds a guide I haven't seen, such as tariffs or markdowns, that breaks the cost or gross profit assumptions.

I can't tell which from my data, and the Q1 call resolves it. Either way, the Q2 bar sits well below Q1's run-rate. The risk is that the bar is low for a reason.

I'd resist turning "dividend not covered" into "dividend cut." Cash is $6.9B against $7.0B a year ago, despite weak FCF and about $2.4B of annual dividends. But if the dividend is cut, I'm out.

The tape¶

I'll take n=2 as a caution against chasing. Your anchors are insider purchase prices a few days after each gap, while today's +10.5% runs from the gap-day close. The data I have doesn't allow a clean comparison. The practical lesson stands either way: bounces in this stock have run about 10% and then needed fundamentals to extend them.
On OBV, we agree on the arithmetic. The disagreement is whether the two event days are a verdict or noise.
The levels that settle it are 38.77 and 34.47. A daily close above 38.77 with OBV confirming is constructive. A daily close below 34.47 puts all three timeframes down.

Revised sequence¶

Today, read the 10-Q and the Q1 call. I'm looking for:
the split of the ~$130M between recurring opex, one-time items and tax;
revenue by geography and channel (Greater China, North America, wholesale vs Nike Direct), which tests whether −4.3% is broad or concentrated;
the Q2 margin guide and tariff commentary. Tariff costs already in the P&L are inside the 42.8%, but inventory accounting can delay them, so the call matters here.
Pull Form 4s filed since 10-02. This is the insider check that actually has information. My inference, not in the data, is that earlier rounds were bought 3 to 14 days after each post-earnings gap. If no one bought at $32–38 in this window, I'll weigh that as a negative.
Starter (about 1%) only if the 10-Q shows mostly recurring cost savings and the guide isn't materially worse than about −4% revenue and about 41% margin. Entry would be in the 36.56–37.18 zone or lower.
Main position after the December print, if both add-tier conditions pass.
Final tranche on a weekly close above 42.88.

Where we still differ¶

You say "cushion until shown otherwise." I'd say "a cost step-down of unknown durability, against a low bar," and the 10-Q should settle that within days. We agree that:

revenue is the weakest link;
a status-quo print is a failure;
no one should size this stock for a stop to hold through a gap.

What I'd keep is the setup. At 1.2x sales and a 4.3% yield, the stock is priced for the trough to persist. If the cost reset is real and revenue declines narrow, even a modest beat on a $0.37 implied bar re-rates it. If it isn't, the tiers above keep me out. Bull Analyst: # Bull Final Reply: One Variable, Priced Low, and I Wait for the Grade

The bear has pushed this debate to a good place. We now agree on the test, so I'll concede what the last round earned, fix my own plan, and show where the bear still overreaches.

What I concede¶

My starter trigger was incoherent. A guide of about -4% revenue at a 41% margin works out to gross profit of roughly -3%, which is my own stand-aside tier. I can't use the status quo as a buy signal.
"The Q2 bar sits well below Q1's run-rate" is withdrawn. Q2 is seasonally stronger than Q3 in both years, and Q4 FY26 is missing from the feed.
The cost line is lumpy. Its YoY changes were +10, +27, +129 and -130, so one quarter isn't a reset.
Over two years, gross profit is down 8.7% (5,257 → 4,798) and below-GP costs are down only 2.9% (4,206 → 4,086).
If the saving is demand creation (marketing), it is recurring and still negative. I'd count it against the thesis.
Restructuring charges not yet taken would also count against it.
The tariff and inventory-timing risk is one-way. Q1 is also the seasonal margin high, so 42.8% may flatter the run-rate.
At $40 the level-based ratio is about 1.1:1. The information from the print has a price.
23.4x forward isn't a trough multiple.

Where the bear overreaches¶

1. "The cost reset earns nothing" is true only at the status quo¶

Net income as a share of gross profit sat at 14.8% because costs fell as gross profit fell. That is how the reset offset the decline. It also means the ratio is the thing that moves when gross profit stops falling.

Holding the ~$130M lower below-GP cost level (the 10-Q question) and the Q2 FY26 base of $5,045M gross profit and $792M net income:

Q2 FY27 gross profit YoY	Net income (approx.)	EPS	vs $0.53
-3.1% (status quo)	~$768M	~$0.52	-2%
-1%	~$872M	~$0.59	+11%
0%	~$922M	~$0.62	+17%

Method: I treat the below-GP line as one block, tax included, and use about 1.485B shares. The real sensitivity is somewhat lower after tax, so treat these as rough.
Sensitivity: Each 1% of gross profit is about $50M, or about 3¢ a share. A three-point gap in gross profit is worth about 10¢, roughly 19% of quarterly EPS.
It cuts both ways. A -5% gross profit print would hurt just as much, which is why the tiers key on gross profit dollars.
The recovery path: The 520bps conversion gap to two years ago (14.8% vs 20.0%) is the upside. It closes only through gross profit dollars.

This changes my checklist. A status-quo print produces about $0.52, so my "EPS ≥ $0.50" line was too easy. The add tier should require EPS of about $0.57 or more and a beat versus consensus. I couldn't retrieve consensus, so that comparison is open.

2. The confirmation triggers charge a second toll¶

The bear rejects $40 on a 1.1:1 ratio built on the 200 SMA as the target. Apply the same yardstick to the bear's own trigger:

From 42.88, the 200 SMA (46.27) is only +7.9% away.
The nearest reference below, 38.77, is -9.6% away. That is about 0.8:1.

So either the 200 SMA isn't the right target, in which case $40 looks better than 1.1:1, or waiting for 42.88 is worse than buying after a fundamental pass. A fundamental pass is the information. I'd use price levels as invalidation lines and as a ladder for sizing, not as a second entry fee.

The plan, with the starter fixed¶

Now: I hold no position.
Read the 10-Q: the overhead vs demand-creation split, pending charges, and revenue by region and channel.
Read the Q1 call for the Q2 guide.
Pull any Form 4s filed since 10-02.
Conditional starter (1% at most): only if the call's guide implies gross profit ≥ -1% (roughly $12.15B at 41.1%), the 10-Q shows overhead savings, and no large charges are pending. If I can't verify the guide, there is no starter. A guide is an input, not a forecast of the print. The bear will say a guide is still a forecast. It is, but it comes from management and arrives before the print.
Main position: after the Q2 print, only if all of these hold:
gross profit ≥ -1% YoY;
EPS ≥ ~$0.57 and at or above consensus;
H1 operating cash flow ahead of H1 FY26;
dividend unchanged.
Final tranche: a weekly close above 42.88.
Out or no position:
gross profit worse than -3%;
a dividend cut;
a cost saving that turns out to be marketing or one-time;
a daily close below 34.47, which puts all three timeframes down.

Size for a 15% gap, not for the stop distance.

Where we stand¶

	Agreed	Still disputed
Weakest link	Revenue
Status-quo print	Failure
Stops	Don't hold through NKE's gaps
Dividend cut	Exit
Core test	Gross profit dollars plus cost durability
Pre-print exposure		A guide-conditional starter (bull) vs none (bear)
Entry trigger after a pass		Fundamentals trigger, price sets the ladder (bull) vs fundamentals plus price confirmation (bear)

Final stance¶

I'm constructive but conditional, with no position today.

The bear is right that this is a falling knife on the tape and that revenue is unresolved. But NKE has been reduced to one variable that will be graded within about two months (the late-December date is unconfirmed). Because costs are roughly 85% of gross profit, that variable has convexity. A flat gross profit line turns a -2% EPS print into about +17%. The stock trades at 1.2x sales with a 4.3% yield, the dividend is covered about 1.0x by forward EPS, and cash is only 1.7% below last year's level.

The bear says to wait for the print and for price. I agree on the print, but price confirmation is where I'd pay too much.

What I couldn't verify: the Q1 call and 10-Q, consensus, tariff exposure on Vietnam, Indonesia and China sourcing, Form 4s after 9/15, and Q4 FY26. Each of these can move the plan. If gross profit comes in at -3% again, the bear was right, and I stay out. Bull Analyst: # Bull Close: The Add Tier Is Hard by Design, and I've Priced That In

The bear's seasonal arithmetic is right, so I'll start with what I'm giving up.

What I concede¶

The base case is the stand-aside tier. Gross profit stepped up +2.5% and +2.1% from Q1 to Q2 in the last two years. A −3.1% YoY print (about $4,889M) is a normal +1.9% step. The −1% add floor needs +4.1%.
My payoff table was one-sided. With the ~$130M saving reversing, a status-quo print is about $0.43 (−19% YoY), and −1% gross profit gives $0.50, below my $0.57 bar. The add tier is a joint condition.
I can't call the cost line a reset. Below-GP costs rose from 36.0% to 36.4% of revenue. They fell with revenue and didn't get ahead of it. Overhead, marketing, tax and timing are indistinguishable in my feed. I also haven't opened the 10-Q or the call in this exchange, so cost durability is still a hypothesis.
A starter at $37.42 buys information the market has had for three weeks. I'm changing it (see below).

Where I still push back¶

1. "Twice the seasonal step" can be two small deviations¶

GP −1% YoY is about $4,995M. These combinations get there:

Path	Q2 revenue	Sequential step	Q2 margin	Sequential step
Normal margin step	$12.15B	+8.4%	41.1%	−170bps
Split	$12.04B	+7.4%	41.5%	−130bps
Normal revenue step	$11.89B	+6.0%	42.0%	−80bps

The middle row asks for revenue about 1pt above the observed +6.0–6.6% range and margin about 30–50bps better than the observed −160 to −180bps. That is within the size of recent moves: the YoY margin delta went −300, −130, +60bps. Some of that came from easier comps.

The seasonal prior is also softer than "n=2" suggests. The Q2→Q3 margin step was −210bps in FY25 and −40bps in FY26. Both samples were drawn during a margin decline, which probably inflates the step-down. I can't quantify that.

None of this makes a pass the base case. My odds, which are judgment and not data: add tier ~20–25%, status quo ~45–50%, fail ~25–30%. That is a stock you wait on.

2. Waiting isn't free, but it still wins¶

The bear says nothing is lost by waiting. In the pass branch, I pay about 7% more ($40 vs $37.42). At 20–25% odds, that costs about 1.5%. In the fail branch, the gap history is −10.5% and −15.5%, plus the October drop. At 25–30% odds, that costs about 3.5% of a full position. I'm not counting the status-quo branch because I have no basis for its sign. Waiting wins by roughly 2:1, so I'm not fighting the bear on it.

3. What the stock costs if a pass happens¶

The 23.4x forward multiple is on trough earnings. Here is the multiple on $45B of revenue, slightly below TTM $45.9B, at higher net margins. Each point of net margin is about $450M, or $0.30 a share, on about 1.485B shares.

Net margin	Net income	EPS	P/E at $37.42
6.35% (Q1 FY27)	$2.86B	$1.93	19.4x
7.5%	$3.38B	$2.27	16.5x
8.5%	$3.83B	$2.58	14.5x
9.07% (Q1 FY25)	$4.08B	$2.75	13.6x

This is conditional on revenue holding, and 4% less revenue scales every row by about 0.96. It is the revenue question again, and the bear is right that the market won't pay for it before revenue shows. But it explains why I'd pay $40 after a pass. At 8.5% net margin that is about 15.5x.

4. The dividend cliff isn't near, though the coverage is thin¶

The bear says cash is flat only because of an unseen Q4. Both endpoints are reported balance sheets, though: $7,024M in Aug-25 and $6,903M in Aug-26. Over the same period, derived total liabilities (assets minus equity) fell from $23.9B to $22.6B, down about $1.3B. The feed has no debt line, so this is derived. It suggests the dividend wasn't funded by net new borrowing.

That doesn't make 0.98x coverage safe. It says the problem is Q2 operating cash flow, not this quarter's cash. A cut is still my exit.

The revised starter¶

I'm turning it into a resting bid, not a purchase.

Size and price: at most 1%, bid at 36.56 (the 10 EMA) or lower. Both of us expect a pullback given the daily TD-9 at −9 and the OBV divergence, so I'd be buying where the market is already likely to go.
Gate: the 10-Q must show savings in overhead and not marketing, with no large pending charges.
Cost of disagreeing: if the bear wants zero, the difference is about 15bps of portfolio risk. I won't fight over it.

Final plan¶

Now: hold no position. Read the 10-Q (overhead vs demand creation, pending charges, revenue by region and channel) and the call (Q2 guide, tariffs).
Add the main position only after the Q2 print, and only if all of these hold:
gross profit ≥ −1% YoY;
EPS ≥ ~$0.57 and above consensus (not retrieved);
H1 operating cash flow ahead of H1 FY26;
dividend unchanged;
a daily close above 38.77 with OBV up.
Stand aside if gross profit is −3% or worse, or EPS is below ~$0.45. The $0.45 line is where the saving would look one-time.
Exit on a dividend cut, a saving that turns out to be marketing or one-time, or a daily close below 34.47.
Sizing: size for a 15% gap, not the stop distance.

Where we land¶

Item	Status
Revenue is the weakest link	Agreed
Status quo is a failure	Agreed
Main position only after the print	Agreed
Entry confirmation at 38.77 with OBV	Agreed
Dividend cut means exit	Agreed
≤1% resting bid at 36.56 or lower, gated on the 10-Q	Disputed, worth about 15bps

I'm constructive but conditional, with no position today. The bear is right that the base case is another quarter of falling gross profit dollars, and that I shouldn't own the stock on that. What I'm holding is narrower. The stock is cheap only if gross profit stops falling, and one quarter will show whether it has. The late-December date is unconfirmed.

Still unverified: the 10-Q and call, consensus, Q4 FY26, tariff exposure on Vietnam, Indonesia and China sourcing, Form 4s after 9/15, and the Q2 report date. Any of them can change this plan.

Bear Researcher¶

Bear Analyst: # The Bear Case for NKE: A Base Effect Dressed Up as an Inflection

You flagged your own weak points, which makes this easier. I'll grant that the balance sheet is real: $6.9B of cash, a 2.08 current ratio, and cash roughly flat from $7.0B a year ago. I'm not arguing insolvency. I'm arguing that the "inflection" you're paying for is mostly base effects, seasonality and a cost line neither of us can see.

1. "−30% to −2%" is a base effect, and gross profit dollars fell¶

Q1 FY26 was already the −30.8% quarter. Against that wrecked base, Q1 FY27 net income of $712M is flat at a low level, and still 32% below Q1 FY25 ($1,051M). EPS is $0.48 against $0.70 two years ago. "Stopped falling" isn't "recovering."

Here is what drove the quarter: - Revenue fell $507M. - Gross profit fell $145M (4,798 vs 4,943). - At last year's margin, the revenue drop cost about $214M of gross profit. The 60bps margin gain added only about $69M. The revenue loss outweighed margin repair roughly 3 to 1. - Net income fell only $15M, so about $130M of cushion came from below the gross profit line. That could be opex, tax or other items, and the feed shows operating income as "unavailable" in every period.

The quarter your thesis rests on is held up by lines we can't inspect. The restructuring and layoff headlines suggest cost cuts, though that's my inference. Cost cuts at a company losing share to a record-setting Adidas is harvesting, not turning.

This also undercuts your $1.2B arithmetic, which assumes $45B of revenue holds. Operating leverage cuts both ways, and revenue is 13% below Q1 FY24 and just fell 4.3% against a +1.1% comp.

2. Your margin table mixes seasons¶

	Q1 (Aug)	Q2 (Nov)	Q3 (Feb)	Q1→Q2
FY25	45.4%	43.6%	41.5%	−180bps
FY26	42.2%	40.6%	40.2%	−160bps
FY27	42.8%	?

Q1 was the highest-margin quarter in both prior years, so: - "260bps off the trough" compares an August quarter to a February quarter. The like-for-like gain is 60bps. - "Hold 42.8% in December for +220bps YoY" assumes something that didn't happen in either of the last two years. A normal seasonal step-down lands Q2 near 41.0–41.2%, or +40–60bps YoY. That is the same modest improvement we have now, not a recovery.

So checklist item #1 is mis-set. Missing it proves little, and meeting it would be unusual.

You said Adidas proves demand exists. I agree, and that is the bear case: the category isn't the problem, NKE is shrinking inside it. Add lululemon's deepening Americas slump (premium North American demand), China, and teens shifting to fashion. These are headlines only, but roughly 7 of 19 are negative against about 4 mildly constructive, all pointing the same way.

Revenue comps also aren't getting easier. The last three quarters were +1.1%, +0.6% and +0.1%, a flat base, and Q1 still fell 4.3%. "Less promotional clearance" and "less demand" produce the same print, and you've labeled your version an inference.

4. The dividend is the last lever left¶

9M FY26: FCF was $685M against about $1.8B of financing outflows, which is roughly the dividend.
Q1 FY27: FCF was −$64M against a dividend of about $600M a quarter.
Capex was up 65% over nine months while operating cash flow fell 62%. That is more spending on a shrinking top line.
The dividend is about $2.4B a year. That is roughly 101% of forward EPS and 136% of TTM FCF, and TTM FCF is itself flattered if the odd Q4 in the snapshot is real.

On "three years of cash": that cash is working capital against $11.4B of current liabilities and roughly $11B of implied debt and leases. It also already fell $660M this quarter. You inferred that buybacks are halted, which means the buyback was the first lever and the dividend is the next. The CFO also changed on 9/1. I won't predict a cut, but an uncovered dividend, a new CFO and no buyback is exactly how rebasing happens. The yield buyer is the marginal bid on this stock, and a cut removes it.

Equity up 13% is not an earnings signal. Book value rises when you stop repurchasing stock.

5. You can't discard the TTM P/E and keep the TTM EV/EBITDA¶

Your 12x EV/EBITDA and 0.9x net debt/EBITDA both use the $4.89B TTM EBITDA from the same snapshot you called unreliable. If the implied Q4 (about a 50% gross margin and $1.07B of net income) is the anomaly, EBITDA is overstated. My rough estimate puts EV/EBITDA in the low-to-mid teens. Leverage still isn't alarming, but "12x" isn't a clean number.

On earnings, the forward EPS of $1.60 sits below TTM $2.08, and below a crude annualization of the three reported quarters (about $1.81). The Street is modeling lower earnings, not a rebound. A "trough" stock at 23.4x forward earnings with shrinking revenue is already paying for the recovery. Being 47% off the high isn't cheap when EPS is down 31% in two years.

6. Your stop doesn't protect you against how this stock trades¶

The big gaps were −10.5% on 12-19, −15.5% on 04-01, and the 10-01/10-02 spike on 112M and 143M shares. The 10-02 bar opened at 32.55. A stop at 34.47 fills at the gap, not at 34.47. The late-December print you're buying into is the next gap risk, so your real downside is not 8%.

Even on your own levels, +14.6% to the weekly stop (42.88) against −14.6% to the 31.97 swing low is 1:1.

If those October volume spikes were the Q1 FY27 reaction (the quarterly cadence suggests it, though my tools don't confirm it), then the market saw the exact print you call an inflection and sold it to $31.97.

The bounce itself has weak support: - Price is only 0.65% above a falling 50 SMA (39.97 → 37.18), after three closes below it last week. - OBV is lower than on 09-21 while price is higher. - The daily TD-9 is at −9. - Monthly closing highs have stepped down every month since January. A monthly buy setup can print for months in a downtrend, and October is still forming. - Retail is 93% bullish on 15 labeled posts, with "$40 this week" and "Shorts can't make this red." You discount it too, but that is the language of crowded bounces.

7. The insider signal is stale and has lost money twice¶

Both buying rounds followed gaps (12-19, 04-01), and both lost money: −35–39% and −12%. About $9M is roughly 0.016% of a $55.6B market cap, a signal but not a catalyst. The insider feed ends 9/15, so it says nothing about the $32–34 window after the print. Don't count insiders as having bought this low.

Parker not selling at −45% is just the absence of selling at a low. He sold about $45M near the highs.

8. The tariff gap hits your entire thesis¶

You named this gap yourself. The thesis is gross margin repair, and the unquantified variable is tariff exposure on Vietnam, Indonesia and China sourcing. Add 97% odds of no cuts and the inflation and $4.33 gas headlines, and there is no macro help. I'll grant that recession odds are only 8%. But missing data on tariffs isn't missing risk.

Your question: which checklist item is the weakest link?¶

Operating cash flow plus the dividend (#3 and #4) is the weakest link. Item #1 is mis-calibrated, as shown in section 2.

The bigger flaw is sequencing. You call the late-December print the test, yet you'd scale in at 36.56–37.18 before it. If the print is the test, wait for it. Paying about $40 after a pass costs roughly 7% more than $37.42. Owning through a miss risks a 10–15% gap. That asymmetry favors waiting.

Bottom line¶

NKE is a bounce inside a weekly and monthly downtrend. It trades at 23x forward earnings on shrinking revenue and a dividend that earnings and FCF don't cover. Its "stabilization" is a base effect that the seasonality and gross-profit math both undercut. I'd stay out or underweight, and I'd revisit if: 1. Q2 shows revenue declines narrowing and positive operating cash flow. 2. OBV confirms the rally. 3. The weekly close clears the 42.88 supertrend.

Until then, this is a falling knife that has paused. Bear Analyst: # Bear Reply: A Checklist the Status Quo Can Pass

You made real concessions, so I'll grant what's right in your reply. The like-for-like margin table is correct: −320, −300, −130, then +60bps is the first positive comparison in the data. Sizing for gap risk instead of trusting a stop is also correct, and moving the main purchase to after the print is the best change you made. Here is what's left.

1. "Two independent lines" is one line and a hole¶

Gross profit dollars, year over year:

Quarter	GP change	GP %	Net income YoY
Q1 FY26	−$314M	−6.0%	−30.8%
Q2 FY26	−$344M	−6.4%	−31.9%
Q3 FY26	−$145M	−3.1%	−34.5%
Q1 FY27	−$145M	−2.9%	−2.1%

The gross profit decline was exactly $145M in both Q3 FY26 and Q1 FY27. Yet net income went from −$274M to −$15M, a swing of about $260M. All of it came below the gross profit line, in lines we've both said we can't see. Whatever drove it (opex cuts, a Q3 charge rolling off, tax), it wasn't margin repair. Gross profit dollars stopped getting worse two quarters ago, while earnings were still collapsing.

Your own sizing of the margin gain is about $60M a quarter, or roughly 3–4¢ a share. At +60bps a year, closing the 260bps gap to Q1 FY25 takes more than four years.

The third line, revenue, has decelerated every quarter: +1.1%, +0.6%, +0.1%, −4.3%. The margin and cost lines are improving, and the line that decides whether they last is deteriorating.

2. Your revised checklist passes on a status-quo print¶

Revenue of $11.9B is a +6.0% sequential step. That matches last year's seasonal step exactly (11,720 → 12,427) and trails FY25's +6.6%. It's the same −4.3% decline repeated.
Gross margin of 41.1% is −170bps sequentially, in the middle of the normal −160 to −180bps seasonal drop.
Gross profit at those levels is about $4.89B against $5.05B, which is −$154M (−3.1%). That would be five straight quarters of falling gross profit dollars in the periods we can measure.

Your pass case is another quarter of the decline you're calling a trough. The checklist also has no EPS line. A real stabilization test is gross profit dollars flat or up YoY. At a 41.1% margin that needs about $12.3B of revenue (−1.2%), not $11.9B.

3. The Street math cuts against you¶

If $1.60 is a fiscal-year number, your arithmetic gives $0.37 a quarter for Q2–Q4. That is about 30% below last year's Q2 EPS of $0.53. So the consensus treats Q1's −2% as an exception, not a trend, and the stock trades at 23.4x that run-rate. A trough multiple would be well below 23x.

I can't tell whether $1.60 predates the print or is a next-twelve-months figure. Neither of us has guidance data.

On the dividend, $1.60 of forward EPS against $1.64 of annual dividends is 0.98x coverage. The "2.9 years of cash" figure says how long the balance sheet can fund the payout, not whether it's covered. The snapshot's TTM FCF of $1.77B also implies a Q4 FY26 FCF of about $1.16B, because Q2 plus Q3 FY26 was $670M and Q1 FY27 was −$64M. So roughly two-thirds of TTM FCF sits in one quarter we can't see, in a snapshot already flagged as unreconciled. The three visible quarters produced about $0.6B against about $1.8B of dividends.

4. The tape¶

This bounce looks like the last two. After the 12-19 gap, insiders bought at $58–61 and the January closing high was $64.59, about +10%. After the 04-01 gap, insiders bought at about $42.4 and the May closing high was $46.46, again about +10%. Each bounce topped within a month or two, was followed by a lower monthly high, and then by the next gap down. That is n=2 with approximate entry points. Today's bounce is already +10.5% from the 10-02 close.

Nothing fundamental has changed since 10-02 except a news flow that skews negative (Adidas, lululemon, China, Zacks).

OBV. I agree the event days (255M shares) explain most of the gap. That is the market's verdict on the print. Price has retraced above its 09-21 level (37.42 vs 36.10), but OBV has recovered only about 29% of its drop (119M of 406M). The latest bar is also the lightest-volume bar in the 30-session window, though it may still be forming.

Risk/reward. Your 2.1:1 assumes the best entry (36.56, not the current price) and the farthest target. From 37.42 it's +23.6% to the 200 SMA against −14.6% to the swing low, or 1.6:1. Reaching that target means clearing 38.77, the falling 50 SMA and the weekly supertrend at 42.88. A ratio needs a win probability, and the only base rate on the table is your own count of three down gaps in four events.

5. The starter doesn't fit your own logic¶

You say the 7% premium for post-print information is worth paying. A starter now buys none of that information. It buys exposure to a gap you've said skews down, and it sits at 1% of the portfolio, so it can't matter much either way: 15bps at risk against roughly 10bps if the bounce adds another 10%. That's a placeholder, not a thesis.

Your conviction trigger is also available today. You said the 10-Q and the call transcript will show whether the ~$130M cushion is SG&A or one-offs. Read those first. If the cushion is durable cost savings, I'd take that seriously. Buying before reading is backwards.

Your insider check, "no director selling," has no information at −45%. The insider feed ends 9/15, so we can't see whether anyone bought at $32–34. Neither reply has quantified the tariff exposure on Vietnam, Indonesia and China sourcing, and the margin-repair path runs straight through it.

Bottom line¶

We've narrowed the question to whether Q1's net income is the start of a recovery or a one-quarter cushion. The evidence says cushion until shown otherwise: - Gross profit dollars were flat in their rate of decline for two quarters. - Revenue is deteriorating. - The Street's implied numbers have earnings falling again. - The dividend isn't covered by forward EPS or visible FCF. - The weekly and monthly trends are down.

My stance on NKE is to avoid or stay underweight, with no starter before the print. I'd turn constructive on: 1. The 10-Q showing the cushion is recurring SG&A savings. 2. Q2 gross profit dollars flat or up YoY (about $12.3B of revenue at a 41.1% margin). 3. A daily close above 38.77 with OBV confirming, or a weekly close above 42.88.

Until then, the levels that matter on the way down are 34.47, 33.30 and 31.97. A dividend rebase would put even those in question. Bear Analyst: # Bear Final Reply: Agreed on the Test, Not on Owning NKE Before It's Graded

You've moved a long way, and the GP-dollar tiers are a better test than anything I proposed. I'll concede what your last reply earned, then show what's left.

What I concede¶

The cost step-down is real against a clean comp. Below-GP costs were $4,206M, $4,216M and $4,086M in the last three Q1s. I was wrong to treat the whole gap as a black box. It is about $130M in a line neither of us can decompose.
The Street math was bad on both sides. My flat $0.37 a quarter ignored seasonality. Q2 has been stronger than Q3 in both years (0.78 vs 0.54, and 0.53 vs 0.35), and Q4 FY26 is missing from the feed. I can't tell whether $1.60 implies growth or decline, so I'm withdrawing "30% below last year's Q2." Your "the Q2 bar sits well below Q1's run-rate" fails for the same reason. Two points survive: 23.4x forward is not a trough multiple, and $1.60 covers the $1.64 dividend about 1.0x.

1. The cost reset offsets the decline; it doesn't earn anything¶

	Q1 FY25	Q1 FY26	Q1 FY27
Net income / gross profit	20.0%	14.7%	14.8%

You said this isn't operating leverage, and I agree. That is the problem. About $130M of cost came out, and conversion of gross profit to net income moved 10bps, still about 520bps below two years ago. Costs fell just enough to offset the gross profit decline. For EPS to grow, gross profit dollars have to grow, and that comes back to revenue.

The line is also lumpy. Its YoY changes were +10, +27, +129 and −130. It has moved about $130M in each of the last two readings, in opposite directions, so its volatility is as large as the whole inflection. One quarter at a lower level isn't a reset, and with Q4 FY26 missing I can't see the sequence.

"Recurring" also doesn't mean "good." Nike's income statement splits demand creation (marketing) from operating overhead, and my feed shows neither. Cutting marketing while Adidas posts a record quarter would be recurring and self-defeating. The restructuring headline is also an unread headline, but severance usually arrives as charges and cash outflows after the savings are announced. That's an inference, and the 10-Q should say whether those charges have been taken yet.

2. Your starter trigger lands in your own stand-aside tier¶

You'd buy a starter if the guide is "no worse than about −4% revenue and about 41% margin." That works out to:

Revenue: $12,427M × 0.96 = $11.93B
Gross profit: $11.93B × 41% = $4.89B
Versus $5,045M last year: about −$154M, or roughly −3%

That is right on your stand-aside line, so the starter triggers on the outcome your table says to avoid. The 10-Q also can't answer the revenue question, which you named as your weakest link. If the starter requires a guide consistent with GP ≥ −1%, that is your add tier, and you'd be forecasting the print, not hedging it.

3. The information isn't free¶

You'd add the main position at about $40 after a pass. At $40 the stock is at 25x forward EPS with a 4.1% yield. On your own levels:

To the 200 SMA (46.27): +15.7%
To the daily stop (34.47): −13.8%, about 1.1:1
To the swing low (31.97): −20%, about 0.8:1

The EPS ≥ $0.50 test may also not be a stretch. If Q2 consensus is in the mid-$0.40s, which the seasonal shape makes plausible, passing means a modest beat of a number already capitalized at 23x. Waiting still beats buying now, but a pass only pays if it also clears 38.77 and 42.88, which is why I tie my triggers to price confirmation.

4. The margin comparison has a one-way risk¶

You flagged that inventory accounting can delay tariff costs. That delay only runs one direction: costs on inventory bought earlier flow into later quarters, so 42.8% may flatter the run-rate. Q1 is also the seasonal high for gross margin, as it was in both prior years. Neither of us has tariff data on Vietnam, Indonesia or China sourcing, and the margin thesis depends on it.

Where we land¶

We agree on four things:

Revenue is the weakest link.
A status-quo print is a failure.
Stops don't hold through NKE's gaps.
A dividend cut means you're out.

The remaining disagreement is whether to put capital in before the test that decides the thesis. Your starter buys a read of the 10-Q, which speaks to cost durability. Revenue, the part that decides whether the cost line matters, stays unresolved until the December print. So I would not take the starter.

Final stance: avoid or underweight NKE, with no position before the Q2 print¶

I'd turn constructive on:

The 10-Q showing the step-down is mostly operating overhead, with demand creation held and no large restructuring charges still to come.
Q2 results with GP ≥ −1% YoY (about $12.15B of revenue at 41.1%), EPS ≥ about $0.50, H1 operating cash flow ahead of H1 FY26, and the dividend unchanged.
Price confirmation: a daily close above 38.77 with OBV confirming, then a weekly close above 42.88.

What would confirm the bear case:

A close below 34.47 puts all three timeframes down, with 33.30 and 31.97 below it.
Gaps skip stops, so size for a 15% gap, not the stop distance.

The bull has narrowed the case to one quarter of one cost line, offsetting a shrinking gross profit line, while revenue deteriorates. That is a reason to keep watching NKE, not to own it. Until revenue turns, it is a falling knife that has paused. Bear Analyst: # Bear Closing: The Pass Tier Needs Twice the Normal Seasonal Step

We now agree on the test: gross profit dollars, cost durability, and revenue as the weakest link. What's left is whether a pass is the base case, whether the cost reset is real, and whether a starter is justified before the print.

What I concede¶

Your convexity math holds. About $50M of gross profit is roughly 3¢ a share, and your table follows from your stated method.
$0.57 is the right EPS bar. The earlier $0.50 line would have passed a status-quo print.
Your second-toll point is fair. From 42.88, the 200 SMA (46.27) is only +7.9% away, against −9.6% to 38.77. I'm dropping 42.88 as an entry precondition. After a fundamental pass, I'd scale in on a daily close above 38.77 with OBV turning up. 42.88 stays as the line where I'd call the primary trend changed, which matters for sizing up, not for starting.
The revised starter is coherent. It no longer triggers on the outcome your own table says to avoid.

1. Your pass tier needs about twice the normal seasonal step¶

Gross profit steps up from Q1 to Q2 every year. Here is what each outcome requires against that pattern:

	Q1 GP	Q2 GP	Sequential step
FY25 actual	5,257	5,389	+2.5%
FY26 actual	4,943	5,045	+2.1%
FY27 at −3.1% YoY (status quo)	4,798	4,889	+1.9%
FY27 at −1% (your add floor)	4,798	4,995	+4.1%
FY27 at 0%	4,798	5,045	+5.1%

The status quo is simply the normal seasonal step. Your add tier needs roughly double that. At the normal ~41.1% Q2 margin, −1% gross profit means about $12.15B of revenue, a +8.4% sequential jump against +6.0% and +6.6% in the last two years. Alternatively, at a normal +6% revenue step, margin would have to fall only ~80bps sequentially instead of 160–180bps.

That is n=2, so I won't oversell it. But the only seasonal pattern in the data says the base case is the stand-aside tier, and the add tier needs a break from it. You've put no probability on that break, and the revenue series (+1.1%, +0.6%, +0.1%, −4.3%) points the wrong way.

2. The payoff table shows the cost saving holding in every row¶

Your table assumes the ~$130M saving persists in every row. Here it is with the saving reversing (Q2 FY26's $4,253M cost base), on your method (cost block including tax, ~1.485B shares):

Q2 gross profit YoY	EPS, saving persists	EPS, saving reverses
−5%	~$0.45	~$0.36
−3.1% (status quo)	~$0.52	~$0.43
−1%	~$0.59	~$0.50
0%	~$0.62	~$0.53

Your "status quo is −2% EPS" holds only if the saving recurs. Without it, the same gross profit print is about −19% YoY.
Your $0.57 add bar is a joint condition. Gross profit at −1% with the saving reversing gives $0.50, a fail.
By your own admission the cost line is lumpy (+10, +27, +129, −130). A joint requirement of "gross profit ≥ −1% and a durable saving" is less likely than either alone.
A beat versus consensus is also required, and neither of us retrieved consensus.

3. The "reset" tracked revenue; it didn't get ahead of it¶

Q1	Below-GP costs	Revenue	Costs / revenue
FY25	4,206	11,589	36.3%
FY26	4,216	11,720	36.0%
FY27	4,086	11,213	36.4%

Revenue fell 4.3% and costs fell only 3.1%, so costs as a share of revenue rose about 45bps. That fits costs flexing down with a smaller top line, not a structural step-down. The block includes tax and other items, so I can't isolate overhead, and I'm not claiming there are no savings. But the data gives no evidence for a cost base that got lighter relative to sales. The 10-Q has to show that, and the restructuring charges may still be ahead.

4. The guide-conditional starter buys public information at a price that already reflects it¶

You say reading the guide and 10-Q is free. It's also public, and it has been for about three weeks. If the 10-01 and 10-02 volume was the Q1 reaction (the cadence suggests it, my tools don't confirm it), the market:

traded 255M shares in two days;
hit $31.97;
has since retraced 17% off that low and 10.5% off the 10-02 close.

Whatever the call said, the market has had three weeks to price it. The unpriced information is the Q2 print, and you agreed to wait for it. Your own rule is to pay a premium only for information you don't have yet. A starter based on a document the market has already read fails that rule, at a price that has already moved.

What stays on my list¶

The dividend: $1.64 annual against $1.60 forward EPS is 0.98x coverage, with FCF negative in Q1 FY27 and no buyback left to cut. You'd exit on a cut, which is the right call, but it shows the position has a named cliff.
The cash comparison: Cash is within 1.7% of last year only because it rose $539M between Aug-25 and May-26. That rise relies on a Q4 FY26 that neither of us can see, and cash then fell $660M in one quarter.
The tariff gap: The Q1 margin is the seasonal high, tariff costs through inventory accounting can lag, and neither of us has data on Vietnam, Indonesia or China sourcing.

Where we land¶

	Status
Weakest link is revenue	Agreed
Status-quo print is a failure	Agreed
Stops don't hold through gaps	Agreed
Dividend cut means exit	Agreed
Fundamentals pass before the main position	Agreed
Price confirmation before entry	Narrowed: 38.77 with OBV, not 42.88
Starter before the print	Disputed

Final stance: avoid or underweight NKE, with no position before the Q2 print¶

Current price is $37.42, and I'd turn constructive only on:

The 10-Q showing mostly recurring overhead savings (not marketing), no large restructuring charges still pending, and revenue weakness that isn't concentrated in one region or channel.
The Q2 print with gross profit ≥ −1% YoY (about $12.15B of revenue at 41.1%), EPS ≥ ~$0.57 and above consensus, H1 operating cash flow ahead of H1 FY26, and the dividend unchanged.
Price: a daily close above 38.77 with OBV confirming.

What confirms the bear case:

Gross profit at about −3% or worse. That is the seasonal base case, not an adverse surprise.
A dividend cut.
A cost saving that turns out to be marketing or one-time.
A daily close below 34.47, which puts all three timeframes down, with 33.30 and 31.97 below it.

Size for a 15% gap, not for the stop distance.

The bull's case now rests on one quarter of gross profit dollars growing at about twice its normal seasonal pace, with a cost saving that has to persist alongside it. If both land, the leverage is real. But the position is a conditional bet on an outcome the data doesn't point toward, and nothing is lost by waiting for the print. Bear Analyst: # Bear Final: On Your Own Odds, the Average Print Misses the Pass Line

We've converged on the test: gross profit dollars, cost durability, and revenue as the weakest link. Two things are left. First, what your probabilities imply. Second, the 1% bid.

What I concede¶

Your 7% pass-branch cost is fair. The only up-gap in the tape was +4.9%, so $40 is a reasonable assumption.
The middle path isn't fanciful. $12.04B at 41.5% means revenue −3.1% and margin +90bps YoY. That compares with −4.3% and +60bps in Q1, a modest improvement in each line. Your 20–25% for the add tier is a fair-minded number.
Your P/E table arithmetic checks out, and I accept the derived $1.3B fall in total liabilities. Financing outflows that roughly equal the dividend already said no borrowing funded it. My dividend concern is coverage, not solvency.
I haven't read the 10-Q or the call either. Everything I say about cost durability is a hypothesis too.

1. You cited the wrong seasonal step¶

The Q2→Q3 margin steps (−210bps, −40bps) are a different transition. Your path needs Q1→Q2:

	Revenue step	Margin step
FY25	+6.6%	−180bps
FY26	+6.0%	−160bps
Your middle path	+7.4%	−130bps

The margin step was −180 and −160bps in two different regimes (45% margins, then 42%). It doesn't look like an artifact of the level. Your path needs revenue 80bps above the best observed step and margin 30bps better than the best observed step, at the same time. That is possible. But it is a deviation from a pattern that has been consistent in both years, so I'd keep it at your 20–25% and not raise it.

2. Your odds and your tables put expected Q2 EPS below last year's¶

I used your branch odds, midpoints normalized to 100%, and your two EPS tables. I took −5% gross profit as the representative fail case.

Branch	Odds	EPS, saving persists	EPS, saving reverses
Add (GP −1% to 0%)	~23%	~$0.60	~$0.51
Status quo (~−3%)	~49%	$0.52	$0.43
Fail (~−5%)	~28%	$0.45	$0.36
Probability-weighted		~$0.52	~$0.43

Even if the saving persists in every branch, the expected Q2 EPS is about −2% YoY and well under your $0.57 bar. If the saving doesn't persist, it is about −19%. About 77% of your probability mass sits in tiers where your own plan says don't own the stock.

Your closing argument called the payoff convex, but your table is linear. Each 1% of gross profit is worth about 3.4¢, or 6.4% of EPS. Linear leverage amplifies both tails equally. With fail (28%) more likely than add (23%), it works against the position. The tape's only reactions to prints are −10.5%, −15.5% and +4.9%. That isn't a skew in favor of owning ahead of the print.

3. Your waiting math is a floor, and the bid fails it¶

You computed a pass-branch cost of about 1.6% (7% × 23%) against a fail-branch cost of about 3.6% (13% × 28%). You excluded the status-quo branch because you saw no basis for its sign. Your own tiers call that outcome a stand-aside, so its sign is zero or negative, and 2:1 is the minimum. Applied to the 1% bid: - Pass: about +7% × 23% ≈ +1.6bps. - Fail: about −13% × 28% ≈ −3.6bps. - Net: about −2bps before the status-quo branch.

The 10-Q gate doesn't change that, because the filing is public. If the 10-01/10-02 volume was the Q1 reaction (the cadence suggests it, though my tools don't confirm), the market has had it for three weeks and the stock is up 17% off the low. You told me the bid is worth 15bps. On your numbers it is worth about −2bps, so please drop it. If you want a rule-consistent version, make the 1% part of the post-print add tier, where the information is new.

At today's cost ratio, net margin is gross margin minus 36.4% of revenue. That ratio was 36.3%, 36.0% and 36.4% in the last three Q1s. So your 8.5% row requires a gross margin of about 44.9%, essentially the Q1 FY25 level (45.4%). At the +60bps a year in the data, that takes more than three years. The 14.5x is what you'd pay after a multi-year recovery that revenue must carry. What $37.42 buys today is 19.4x on the Q1 run-rate with the saving intact, or 23.4x on the Street's $1.60. Neither is a trough multiple.

5. Unchanged risks¶

Tariffs and inventory accounting can delay costs into later quarters. Q1 is also the seasonal margin high, so 42.8% may flatter the run-rate. Neither of us has sourcing-tariff data for Vietnam, Indonesia or China.
Dividend coverage is about 0.98x on forward EPS, with Q1 FCF at −$64M, no buyback left to cut and a new CFO since 9/1. You exit on a cut. That cut is the cliff, and it removes the yield bid.
Still unverified by both of us: the 10-Q and call, consensus, Q4 FY26, Form 4s after 9/15, and the Q2 report date.

Where we land¶

Agreed: - Revenue is the weakest link. - A status-quo print is a failure. - Stops don't hold through NKE's gaps, so size for a 15% gap. - The main position comes only after the print. - Entry needs a daily close above 38.77 with OBV rising. - A dividend cut means exit.

Disputed: the pre-print 1% bid. It is worth about ±2bps, so it is a question of discipline more than money.

Final stance: avoid or underweight NKE, with no position before the Q2 print¶

At $37.42, I'd turn constructive only on all of these together: 1. The 10-Q shows the ~$130M saving is overhead, not marketing, with no large pending charges. 2. Q2 gross profit is ≥ −1% YoY (about $12.15B of revenue at 41.1%), EPS is ≥ ~$0.57 and above consensus, H1 operating cash flow is ahead of H1 FY26, and the dividend is unchanged. 3. A daily close above 38.77 with OBV confirming.

The bear case is confirmed by any of these: - Gross profit at −3% or worse, which is the seasonal base case. - A dividend cut. - A cost saving that turns out to be marketing or one-time. - A daily close below 34.47, which puts all three timeframes down, with 33.30 and 31.97 below it.

The bull has rebuilt the case into a conditional, well-specified plan, and I credit that. But on the bull's own probabilities, the most likely Q2 outcome is flat-to-lower EPS, the pass branch is the minority, and a stock at 23x forward earnings needs that minority to happen. There is no cost to waiting for the print.

Research Manager¶

Recommendation: Underweight

Rationale: This debate converged more than most. By the end, both sides agreed that revenue is the weakest link, that a status-quo Q2 print counts as a failure, that stops won't hold through NKE's gaps, that the main position should wait for the print, and that a dividend cut means exit. The only live dispute was a 1% resting bid before the print. Even the bull's closing stance was 'no position today.' So the question is not whether to own NKE now but how cautious to be, and the bear's case is clearly stronger on the evidence.

What the bull got right: the like-for-like gross margin comparison turned positive (+60bps YoY after -320, -300 and -130). Below-gross-profit costs stepped down about $130M against a clean comp. The balance sheet is sound: $6.9B cash, a 2.08 current ratio, and derived liabilities down about $1.3B, so this is not a solvency story. At 1.2x sales with a 4.3% yield, a gross-profit recovery would carry real earnings leverage of roughly 3c of EPS per 1% of gross profit.

What decided it for the bear: (1) Gross profit dollars are still falling. Q1 FY27 was -$145M, the same as Q3 FY26, and revenue has decelerated every quarter: +1.1%, +0.6%, +0.1%, then -4.3%. (2) The cost 'reset' only tracked revenue down. Costs rose from 36.0% to 36.4% of revenue, and nobody has read the 10-Q to confirm whether the saving is overhead, marketing, tax or timing. (3) The seasonal arithmetic puts the base case in the stand-aside tier. A normal Q1-to-Q2 step (+2.1% to +2.5% gross profit) yields about -3% YoY. The add tier needs roughly double the seasonal step. (4) On the bull's own probabilities (about 23% add, 49% status quo, 28% fail), expected Q2 EPS is about $0.52 if the saving persists and about $0.43 if it doesn't. That is flat-to-down YoY, well below the $0.57 pass bar, with about 77% of the probability mass in outcomes where neither side wants to own the stock. (5) Valuation is not a trough multiple: 23.4x forward EPS of $1.60, and 19.4x even on the Q1 run-rate with the saving intact. (6) The dividend is covered only about 0.98x by forward EPS. FCF was -$64M in Q1, buybacks are already gone, and a new CFO started 9/1. A cut would remove the yield bid. (7) The tape is a roughly 10% bounce inside down weekly and monthly trends. It sits just above a falling 50 SMA, OBV is not confirming, and the daily TD-9 is at -9. Prior post-gap bounces topped around +10% before the next leg down, and two of three earnings gaps were large declines (-10.5% and -15.5%).

I'm not going to Sell. The balance sheet is strong, the cost and margin data show some real improvement, and the bull's conditional upside case is credible. The thesis gets graded in about two months. That argues for reduced exposure and clear upgrade triggers, not a full exit.

The evidence also has real gaps. Neither side retrieved the 10-Q or the Q1 call, consensus estimates, Q4 FY26 data, Form 4s after 9/15, the confirmed Q2 report date, or any tariff exposure data for Vietnam, Indonesia and China sourcing. Each of these could move the call.

Strategic Actions: 1. Positioning now (price about $37.42): target about 50% of a standard allocation. If flat, do not initiate. Specifically, do not place the bull's 1% resting bid at 36.56: on the debate's own numbers it carries slightly negative expected value, and its 10-Q gate uses information the market has had for about three weeks. If at or above standard weight, trim toward half into strength in the $37.40-$38.80 zone, below the 38.77 resistance and the falling 50 SMA. Do the trim before the Q2 print, not after a possible gap.

Gap-based sizing: size the residual position assuming a 15% overnight gap on the print, not the stop distance. The prior earnings reactions were -10.5%, -15.5% and +4.9%. The total loss on the residual from a 15% gap should fit the portfolio's single-name risk budget.
Immediate homework, before any change in stance:
Read the Q1 FY27 10-Q and the earnings call. Split the roughly $130M below-gross-profit saving into operating overhead, demand creation/marketing, tax and one-time items. Check for pending restructuring charges, revenue by region (Greater China, North America) and channel (wholesale vs Nike Direct), the Q2 margin/revenue guide, and tariff and inventory-timing commentary.
Pull Form 4s filed since 10-02 for any insider buying in the $32-38 range.
Confirm the Q2 report date (historically late December) and Q2 consensus EPS.
Upgrade triggers to Hold, then Overweight, rebuilding toward a standard allocation in tranches. Require all of the following: (a) The 10-Q shows the saving is mostly recurring overhead, not marketing, with no large charges pending. (b) Q2 gross profit at or above -1% YoY, about $4.99B or better (roughly $12.15B revenue at a 41.1% margin, or $12.04B at 41.5%). © Q2 EPS at or above about $0.57 and above consensus. (d) H1 FY27 operating cash flow ahead of H1 FY26. (e) The dividend unchanged at $0.41. (f) A daily close above 38.77 with OBV turning up. Add the first tranche after (a) through (f). Treat a weekly close above 42.88 (the weekly supertrend) as confirmation of a primary trend change, which justifies scaling to full weight.
Downgrade-to-Sell (exit) triggers, any one of which suffices:
A dividend cut or suspension.
Q2 gross profit at -3% YoY or worse together with EPS below about $0.45, signalling the cost saving was one-time.
The 10-Q or call showing the saving was mainly marketing cuts or non-recurring.
A daily close below 34.47, which turns all three timeframes down, with 33.30 and the 31.97 swing low as next supports.
Status-quo print (gross profit about -3%, EPS about $0.50-0.52, dividend intact): keep the underweight and make no adds. Reassess after the next quarter.
Monitoring: watch OBV against price on any move toward 38.77, the daily TD-9 sell setup resolving, monthly closing highs (each has been lower since January), and any tariff headlines on Southeast Asian or Chinese footwear sourcing.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan's Underweight maps to Sell: reduce exposure rather than exit fully. Gross profit dollars are still falling (-$145M in Q1 FY27), revenue growth has decelerated to -4.3%, and the seasonal base case implies about -3% YoY gross profit at 23.4x forward EPS. The dividend is covered only about 0.98x, and the technicals are a roughly 10% bounce inside down weekly (stop 42.88) and monthly (stop 60.64) supertrends. That bounce sits just above a falling 50 SMA (37.18), with OBV not confirming and the daily TD-9 at -9. I'm not recommending a full exit because the balance sheet is sound ($6.9B cash, 2.08 current ratio) and like-for-like gross margin improved by 60bps. The 10-Q, Q1 call, consensus, Q2 date and tariff exposure were not retrieved, so those gaps argue for trimming rather than a full exit.

Entry Price: 38.05

Stop Loss: 34.47

Position Sizing: Portfolio context not provided. If at or above standard weight, trim toward about 50% of a standard allocation into strength in the 37.40-38.80 zone (38.05 is the upper Bollinger band, below the 38.77 resistance) before the Q2 print. If flat, do not initiate and do not place a resting bid at 36.56. Size the residual for a 15% overnight gap on the earnings print, not for the stop distance. The 34.47 stop is the daily supertrend and is the plan's exit trigger for the residual: a daily close below it puts all three timeframes down. Exit the residual earlier on a dividend cut.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I'll open since nobody else has, and I'll take on the objections I expect from both of you.

The Sell is the aggressive call here, not the timid one. The stock is up about 10.5% off the 10-02 close of 33.87, retail is roughly 93% bullish among labeled StockTwits posts, and people are posting "40 this week" and "shorts can't make this red." The trade is to sell into that, at 37.40 to 38.80, not to wait for a stop to do it later. Selling into crowded enthusiasm is where the edge is.

The setup supports it. NKE is in a weekly and monthly downtrend, with stops at 42.88 and 60.64. The bounce has run into a falling 50 SMA at 37.18 and the upper Bollinger band at 38.05. The daily TD-9 is at -9, and OBV is lower than it was on 09-21 even though price is higher, so volume isn't confirming the rally. The payoff map also looks poor. The nearest ceilings are 38.05 and 38.77, only about 1.7% and 3.6% away. The downside levels are 36.56, 35.68, 34.47 and the 31.97 low, which are 2% to 15% away. To get paid for holding a full position, price has to clear 38.77 and OBV has to turn up. Neither has happened.

To the neutral analyst, who I expect to say the signals conflict: the monthly TD-9 of +9 is real, but the October bar is still forming, so it's provisional. The weekly tier carries more weight, and it says down. MACD crossing zero and RSI at 58 are lagging confirmations of a bounce I'm already selling into. Conflicting signals are why we trim and don't go flat or short. If I'm wrong and it squeezes toward 42.88, the residual half still participates.

On the improving margins, gross margin was up 60bps, but gross profit dollars fell $145M and revenue was down 4.3%. That is margin improvement on a shrinking base, not demand recovery. Forward EPS of $1.60 is below TTM EPS of $2.08, so 23.4x forward is the multiple to use. The 18x TTM figure is distorted because the TTM numbers don't reconcile with the quarterly data. Paying 23x for falling gross profit isn't cheap.

To the conservative analyst, who may point to the 4.3% yield and the insider buying as reasons to hold or buy: the dividend is covered about 0.98x by forward EPS and about 136% of TTM FCF, and Q1 FY27 free cash flow was negative. A high yield on a stock down 47% from its high is a warning as much as an attraction. The insider buying was real, about $8 to $9M, but the buyers are underwater, at 35-39% down on the December buys and about 12% on the April buys. Nobody has bought in six months, including on the slide from 42 to 37 and the dip to 32, and officers have been selling modestly since June. Insiders also haven't shown conviction near these levels.

If the conservative analyst argues for a full exit, the balance sheet is why I disagree. There's $6.9B of cash and a 2.08 current ratio, so the dividend isn't in imminent danger. Going to zero would also give up the turnaround optionality. Moves like -10.5%, -15.5% and +4.9% have hit this stock on heavy volume around roughly quarterly events. That cuts both ways. I'd rather keep a half position sized for a 15% overnight gap than sit in a full position or sell everything and miss a violent upside gap.

There are gaps. I don't have the 10-Q, the Q1 call, consensus, the Q2 date or tariff exposure. A conservative analyst may say that means don't act. I'd say unknowns on a stock with double-digit earnings gaps are a reason to carry less risk into the print, not more. The stop at 34.47 is the daily supertrend. A close below it puts all three timeframes down, and the residual should go then, or earlier on a dividend cut.

I can see a way I'm wrong. A daily close above 38.77 with OBV turning up would mean the bounce has real buyers behind it, and I'd revisit the sizing. Until then, with no position context, my guidance is: if you're at or above standard weight, trim toward half of standard into strength before the Q2 print. If you're flat, don't initiate, and don't leave a resting bid at 36.56. The plan is to sell the strength decisively and keep a small, defined-risk stake in the turnaround. Aggressive Analyst: You both landed real hits, so I'll give those up first.

Calling the leftover half "defined-risk" was wrong. 34.47 is a daily close-below trigger about 8% under the price, on a stock that has gapped 10.5% and 15.5% on over 100 million shares. It tells you when to leave, not what you lose. The dividend-cut exit has the same flaw, because a cut arrives as a gap. Only size limits the damage, and I'll stop calling it anything else. You're also right that I anchored on a fill at 38.05 when 37.42 is already inside my own 37.40 to 38.80 zone. A plan that needs one price can miss, so start selling now. I'm dropping the crowd-fade too. 14 labeled posts out of 15, from one afternoon with Reddit off, isn't an edge. The Sell stands on the weekly and monthly trends, the OBV divergence, the falling revenue and the 23.4x forward multiple. It doesn't need the daily 9 either, and I wouldn't hang timing on it.

Now where I'm holding. The half-versus-quarter fight is smaller than it sounds. Those 7.5% and 5% losses are percentages of a standard allocation, not of the portfolio. The 31.97 washout low is 14.6% below the current price, and the 42.88 weekly stop is 14.6% above it. So the gap between a half and a quarter is about 3.7 points of allocation in either direction. That's a judgment about which tail is likelier, not a reason to flinch.

The conservative's skew argument also proves too much. If three big gaps (-10.5%, -15.5%, +4.9%) show the stock only gaps down, the logical endpoint is zero, not a quarter. Nobody wants zero, because four events don't fix a skew, and October 2 showed buyers absorbing a flush. It opened at 32.55, hit 31.97 and closed 33.87 on 142.7M shares. If that's enough doubt to keep something, keep something that matters.

The residual is the turnaround option, and one print can move it. Net income fell only $15M on $145M less gross profit, after three quarters of declines of 30% or worse. As rough math, assume gross margin dips about 1.6 points from Q1 to Q2, as it did last year. Then revenue down another 4% means gross profit about 3% lower. If revenue just goes flat, gross profit is about 1.5% higher. That swing is what an upside gap would feed on, and the institutional headlines are about as bearish as they get, so I wouldn't bet that there's no upside surprise.

So I'll take the neutral's formula, loss tolerance divided by 0.20. It's the honest version of sizing for the gap. I'd plug in 8% to 10%, which gives 40% to 50% of standard. The conservative plugs in 5% and gets a quarter. That's the real disagreement, a risk budget and not a thesis, and it's the caller's number.

I'd keep the neutral's three tranches with two changes. First, front-load them. Make the first piece the biggest, not a third. The 50 SMA is still falling, and OBV has recovered only 119M of the roughly 406M shares it lost between 09-21 and 10-02, under 30%, while price has more than recovered. Resistance is 1.7% and 3.6% away, and the supports are 2.3%, 4.6% and 7.9% away. If I sell at 37.4 and I'm wrong, the cost is a squeeze to 38.77. If I'm right, it pays much more.

Second, the re-entry rule. Setting it now is right, but a weekly close above 38.77 with OBV back above -1.31B needs another 287M shares of net buying. That's about two and a half times what this whole bounce produced. It will probably trigger well above 39, which is the same lag you held against the conservative's fundamentals rule. I can live with that, because it's what confirmation costs. But I'd use it as the signal to cancel any unsold tranches, not to buy back. A buyback waits for the weekly supertrend flip above 42.88, or a print where the revenue decline narrows and gross margin holds near 42.8%. That avoids selling at 38 and buying at 39, because the residual participates in the meantime.

On 34.47, cutting the residual by half on a close below is fine, and the rest goes if the 33.30 lower band fails. That's a review level, and I won't pretend it protects anyone.

On the missing data, the 10-Q, consensus, Q2 date and tariff read are all fetchable. Don't use them as an excuse in either direction. Don't hold the first sale for them, and don't make the last sale without them.

I'm wrong if NKE closes a week above 38.77 with OBV climbing, and then I stop selling. Until then, sell the strength now, size the residual to a number you can survive a 20% gap with, and keep it big enough to matter if the turnaround is real. Aggressive Analyst: I'll start with what I'm giving up, because some of it was my error and not just emphasis.

First, insiders. I said nobody bought on the dip to 32. That low was October 2, and the insider feed stops at September 15, so I can't see that window at all. The slide from 42 to 37 mostly happened before the print, when insiders are usually blacked out. That silence told me nothing, so I'm withdrawing it. The conservative's reverse reading has the same flaw, because a feed that can't see October can't show an absence of October buying. Pull the Form 4s since October 1. If directors and the CEO bought into 33 to 36 the way they did after December 19 and April 1, that's the strongest bullish fact in the file and I'll say so. If there's nothing three weeks into an open window, the conservative's reading wins.

I'm also dropping the bearish headlines as contrarian fuel. They're titles with no bodies, the same grade of evidence as the 14 labeled posts I already gave up. OBV goes too. If 255M of the 406M it lost came in two days, and it books a 142M-share day as selling even though the stock closed well off the low, then the divergence is mostly two outlier days, not distribution I can read. I'm also retracting "stop selling above 38.77." A cap is a risk limit, not a market view, so a breakout changes where I finish selling, not how much. If it squeezes to 42, that's what the cap costs. And the conservative is right that 31.97 isn't a floor, since a 15.5% gap from here prints around 31.6.

Now something I think changes the debate. The fundamentals report already carries Q1 FY27, the quarter ended August 31, so that print has happened. Nike normally reports in late September, and the only event volume in that stretch is October 1 and 2, at 112M and 143M shares. So we've likely been arguing about numbers the market already priced, and the next scheduled gap is late December, about nine weeks out. That's unconfirmed, and it's the first fetch. If it holds, it cuts against the conservative's reading that the flush was the market rejecting the improvement. NKE is at 37.42 against 36.10 on September 21. The market sold the print for two days and bought it back over thirteen sessions. That's the hardest fact for my own side. It's why I'm selling a retrace into resistance and not shorting, and why there's a residual at all.

On size, the neutral's arithmetic settles most of it. A third at the worst gap we've seen costs about 5.2% of a standard allocation, and a quarter at a 20% stress costs 5%. So quarter versus third is just whether you stress beyond history, worth about a point of allocation. I'm moving off half. The default is a third, a quarter if the caller says 5%, and half only if they really name 10%. The conservative calls the residual insurance sized by what you can afford. Fine, that's exactly what dividing by 0.20 does, and the input belongs to the caller. What I won't do is drop to a tenth by reflex. That's an exit with extra steps, on a tape that just rose 10.5% on a quarter whose numbers were already out. The sentiment feed also mentions an investor event, unverified, which would be an upside gap before December that doesn't wait for a print. Add it to the fetch list.

On rebuilding, the conservative's best hit is that "the decline narrows with margin holding" is the story I rejected. The neutral's version is mine plus a free cash flow gate, which is an improvement. Operating cash flow was already positive at $135M last quarter, so the conservative's gate wouldn't gate anything. I'd tie the first step to what the Sell is actually about, which is gross profit dollars. The Q1-to-Q2 margin drop was 1.8 points two years ago and 1.6 last year. A Q2 margin near 41% means flat gross profit needs revenue down no worse than roughly 1% to 1.5%. That's my estimate, not a forecast. So the first step back, to half of standard, needs gross profit dollars up year over year and free cash flow positive. Full weight needs real revenue growth or a weekly flip above 42.88. Since the residual stays on, I'm not buying back from zero at 42.

So here's where we stand on NKE. Sell. Take about half the trim now around 37.4, work the rest into 38.05 to 38.77 if it's offered, and finish by mid-November at any price. Cap the residual at loss tolerance divided by 0.20, with a third as the default, and hold that cap through the December print whatever price does. Cut it in half on a close below 34.47, and the rest goes if the 33.30 band fails. Fetch in this order: the print date and reaction, the Form 4s since October 1, the 10-Q for capex and cash, consensus, the tariff read, and any investor event before December.

What I won't give up is the shape: sell early and decisively, and don't confuse a risk limit with an exit. What's left is a number only the caller has. Aggressive Analyst: You two have moved me in several places, so I'll say where first.

On pace, the conservative is now more aggressive than I was, and he's right. I argued for front-loading, then left a 38.05 limit sitting in the middle of the plan. I've dropped the daily 9, OBV and the crowd. What's left is weekly and monthly trends down and gross profit falling, and none of that improves at 38.05. The money is also small. If someone goes from full weight to a third, the slice waiting at 38.05 is about a fifth of a standard position, and 3% on that is under a point of allocation either way. That's a reason to stop deliberating. Far over the cap, sell about two-thirds of the trim now. Near the cap, half. Leave one limit at 38.05 for a week, then sell whatever's left. Use dates, not prices.

I also concede two things the neutral landed. The upside is a tail, not a coin flip. Flat revenue needs a 10.8% sequential step from Q1, against 6.0% and 6.6% in the last two years, and the normal step puts Q2 revenue about 4.4% below last year again. So a third is the default, and I'll stop describing the residual as something that has to be big enough to matter. It's a hedge against lag. On insiders, a fresh October cluster would show what directors think, not when they're right, since both earlier clusters were followed by lower lows. I'd read it and not resize on it.

The conservative's round-trip point also helps the Sell more than it hurts. The stock closed 38.10 on September 8, officers sold at 37.59 the next day, and it's 37.42 now. So I'm selling a full retrace into the zone where it traded before the print, with the 38.77 September closing high just overhead and both higher-timeframe trends unchanged. That tells us the market was neutral on the print, and I'll stop claiming it read the print either way.

Now where I still push back. Conservative, your cap is a ratchet. If it can only fall on new information and rise only after the print, you're resizing on things that don't change the gap, which is what you objected to in the crowd and OBV arguments. Only the caller's tolerance, the date, and the gap size you assume should move it, in either direction. Your step to half on a weekly flip above 42.88 also breaks your own rule that nothing raises the cap before the print. The neutral's version, with the rebuild only after the print, is the consistent one.

You're right that free cash flow positive doesn't discriminate. Q2 and Q3 of last year made about $670M combined, so a flat quarter clears it. I'll drop it and use operating cash flow up year over year, with the comparator from the 10-Q. For gross profit, I'd write the number down now so the gate can't be rewritten when results land. Q2 FY26 gross profit was $5.045B. If Q2 gains the same 60bps as Q1, margin is about 41.2%, and clearing $5.045B takes revenue down no worse than about 1.5%. If revenue repeats minus 4.3%, gross profit lands near $4.9B, about 3% lower. That's a hard gate, but it tests a real claim. Then use the neutral's two keys after the print. One key, the fundamentals or a weekly flip above 42.88, takes you to half of standard. Both take you to full. If the print gaps up and you rebuild above it, that's the cost of the rule, and it's what the residual is there to cover.

The 34.47 and 31.97 closes are the tripwires, at fixed prices. They're after-the-fact exits. A 15.5% gap from here prints near 31.6, through both in one session, which is why the cap exists.

The neutral raised the dividend declaration, and it matters. The file shows $0.41 payments dated December 1, March 2, June 1 and September 1. If the declaration comes a few weeks ahead of that, as is usual (I haven't verified it), it lands in mid-November, before the print. That makes mid-November a hard backstop, not a target. A cut is unlikely with $6.9B of cash, but a cut is a gap, and the calendar may hold more than one date.

My call is still Sell. Size the residual at the caller's loss tolerance divided by 0.20, a third if they can't name a number, never above half. If they're already under that size, do nothing, and if they're flat, stay flat. Get there by early November and hold it through the print whatever price does. Fetch the December date and the size of the October gap, the Form 4s since October 1, the 10-Q, consensus, the tariff read, any investor event and the dividend declaration date.

What I won't give up is the shape: sell early and decisively, and don't treat a risk limit as a view or as an exit. The number is the caller's. Aggressive Analyst: There's very little left, so I'll take what the two of you landed, correct one thing I said, and push on a few spots.

On the stress input, I'll take the neutral's framing: 20% is 1.3 times the worst gap in the sample, a maximum and not a one-way valve. Here's a wrinkle. The October 2 open at 32.55 was 9.8% below the September 21 close. I can't split that between drift and gap without the September 30 and October 1 closes, but it suggests October was another large down move. If so, the count is three big down moves and one modest up move, which favors the conservative on skew. That's why I'm comfortable at a third and not a half, and it doesn't change the 20%.

I'm retracting the round-trip claim. My baseline was September 8, three weeks before the event days. Against the last pre-event close we have, 36.10, the stock is up 3.7%. Without the September 30 close, the October gap size and the reason for October 15, "neutral on the print" and "rejected the print" are both unsupported. The Sell stands on the weekly and monthly trends and on gross profit dollars.

I'll take the neutral's ladder. The numbers say Q2 isn't an easy comp. Q1 gross profit of $4.80B plus the normal 2.1% to 2.5% sequential step lands near $4.90B to $4.92B. The $5.045B gate asks for $125M to $150M more than a normal quarter. If it passes, my thesis is wrong, and rebuilding higher is what that costs. The conservative's base-effect worry belongs on the second print, so full weight needs year-over-year revenue growth. I also take standalone Q2 operating cash flow as a veto, sourced from the 10-Q, since the file has no six-month figure.

On the dividend, I recall the same pattern the neutral does, with a declaration in mid-November and ex-dates near the start of each quarter. I haven't verified it. Early November is the target under either reading, and the declaration date goes at the top of the fetch list.

Now my pushback. First, the conservative's October 15 point is good, but it shouldn't hold anything up. If it was a squeeze, we're selling into it. If it was news, it may be the same thing as the unverified investor event on StockTwits, so fetch those together. An earlier confirmed event moves the finish date up by a week and doesn't change the cap.

Second, the neutral is right that nine fetches and five rungs is too much machinery. Only two things can move the plan before the print: the calendar (December print, dividend declaration, any investor event) and the size of the October gap. The Form 4s, 10-Q, consensus and tariff read inform the rebuild and a thesis check. A fetch that shows I misread the quarter would cancel the remaining slice. A fetch that only adds color wouldn't.

Third, a practical point nobody made. If the caller is only slightly over the cap, with an excess under about a tenth of standard, sell it all now and skip the limit order. A staged exit on a tiny excess is deliberation the evidence doesn't justify.

Fourth, I want to be honest about the cost of being wrong. With a third on, a 10% upside gap misses about 6.7 points of standard allocation, and a 15.5% downside gap avoids about 10. That's cheap against the gaps we've seen, and I won't fight the conservative's point that a 20% loss needs a 25% gain to recover. It's also why the residual is a hedge against lag and not a bet.

What I won't give up is the shape. Sell now, don't wait for a price, don't mistake a tripwire for protection, and keep enough of a stake that an upside surprise isn't a total miss. The cost of dithering is real too. The excess stays exposed for every day of debate, and the first slice shouldn't wait on any fetch.

My call is still Sell. The cap is the loss you can absorb divided by 0.20, a third if you can't name a number, never above half. If you're more than double the cap, sell about two-thirds of the excess now. If you're closer, sell half. Leave one limit at 38.05 for a week, then sell the rest at market. Be at the cap by early November, with mid-November as the backstop. Hold it through the December print whatever price does. Halve it on a close below 34.47 and take the rest on a close below 31.97. Rebuild only after the print. Either gross profit at or above $5.045B with operating cash flow not down, or a weekly flip above 42.88, takes you to half. Both take you to two-thirds, and full weight needs revenue growth. If you're already at or under the cap, do nothing, and if you're flat, stay flat. The number is the caller's.

Conservative Analyst¶

Conservative Analyst: I agree with the direction, so let me narrow the disagreement. Weekly and monthly are both down, price needs about 14.6% just to reach the weekly stop, OBV is lower than on 09-21 while price is higher, revenue fell 4.3%, and Q1 free cash flow went negative. My problem is the leftover half position, and calling it defined-risk, because I don't think it is.

The 34.47 stop is a daily supertrend, so it's a close-below trigger, not a protective order. It's under 8% below the current price and about 9% below your 38.05 entry. This stock gapped about 10.5% on December 19 and about 15.5% on April 1, both on over 100M shares. Even the smaller of those from 38 lands near 34, under the stop, before anyone can act. The dividend-cut exit has the same flaw, since a cut arrives as a gap. Those triggers tell you when to leave after the damage, and only position size limits the damage. Sizing for a 15% gap also isn't a stress case, because April was 15.5%. I'd size the residual so a 20% overnight gap is tolerable. Half a standard position hit by 15% is a 7.5% loss against a standard allocation. A quarter position hit by 20% is 5%. That points to a quarter to a third of standard, not half.

On missing a violent upside gap, the events you cited were -10.5%, -15.5% and +4.9%. The one upside gap was about a third the size of the worst downside gap. The optionality is real in the abstract, but this stock's actual record skews down.

On the dividend, 0.98x of forward EPS and 136% of TTM FCF are the friendly versions. The fundamentals report says the TTM figures don't reconcile with the quarterlies. The implied missing quarter would need a roughly 50% gross margin and about $1.07B of net income, so TTM FCF may be flattered too. On the quarters we can see, nine-month FY26 free cash flow was about $685M against $1.78B of financing outflows that look like mostly the dividend. Q1 FY27 was -$64M of FCF against -$618M of financing, and cash fell $660M in the quarter. I agree $6.9B means no cut next quarter. But a cushion being drawn down to fund the payout is a reason to hold less. For anyone leaning on the yield, the quarterly dividend is $0.41, the average daily range is $1.06, and a 15% gap is about $5.60 a share, more than three years of dividends.

You also have an inconsistency. You discount the monthly TD-9 of +9 because October is still forming. Fair. But today's bar has the lowest volume in the 30-session window, so it's probably still forming too, and the daily -9 is just as provisional. I wouldn't hang the timing on it. That matters because the plan waits for 38.05, while price is 37.42, already inside your 37.40 to 38.80 zone. If the sell setup does produce a pullback toward 36.56, a limit at 38.05 may never fill, and you ride a full position down while waiting for a price. I'd start trimming now and stage the rest into strength with a deadline. The Q2 print is probably late December and unconfirmed, so there's time, but not for a plan that needs one specific price.

The 93% bullish figure is 14 of 15 labeled posts from a single afternoon, with Reddit off, and the sentiment report itself calls it statistically fragile. Several unlabeled posts already expect a retest of 36.50 to 36.90, so the crowd isn't as unanimous as you describe. The Sell holds without that "edge," so I wouldn't rest it there.

Your revisit condition also worries me. If we trim near 38 and revisit on a close above 38.77, we sell at 38 and buy back at 39. Set the re-entry conditions now and tie them to what's actually broken, meaning revenue back to growth and operating cash flow positive, not a one-day close with an OBV uptick.

The gaps in the data push the same way. We have no 10-Q, no consensus, no read on tariff exposure from Vietnam, Indonesia and China sourcing, and no macro readings because FRED failed. Prediction markets at 97% for no 2026 cuts also mean there's no rate tailwind. Those unknowns argue for less risk.

So I'd keep the Sell and start trimming now instead of waiting for 38.05. I'd take the residual to roughly a quarter to a third of standard, less if the book can't absorb a 20% gap, and treat 34.47 as a review level, not protection. If you're flat, stay flat. When the neutral analyst says the signals conflict, that's an argument for the smaller residual, not the larger one. Conservative Analyst: We agree on most of it now. Sell is right, 34.47 is a review level and not protection, only size defines the risk, the number comes from loss tolerance divided by 0.20, and re-entry gets set now. What's left is the loss-tolerance input, how fast you get to it, and when you're allowed to buy back.

To the aggressive analyst first. You say half versus a quarter is only about 3.7 points of allocation either way, so it's a judgment about which tail is likelier. But your whole case is that the downside tail is likelier: weekly and monthly trends down, OBV not confirming, 23x forward on falling gross profit. If you believe that, the residual isn't a coin flip. It's insurance against being wrong, and insurance gets sized by what you can afford to lose, not by how far away each tail sits. Also, 31.97 isn't a floor. A 15.5% gap from 37.42 lands near 31.60, under the washout low, while the upside tail needs the weekly trend to flip.

Your turnaround math holds, but it needs revenue to go from -4.3% to flat in one quarter. And look at how the market treated the last improvement. Net income down only 2% after three quarters of 30%-plus declines is the best comparison in the dataset. The heavy days on October 1 and 2 line up with Nike's usual late-September reporting, though nobody has confirmed that. If they were the print, the best-looking comparison in the dataset got a flush to 31.97 on 142.7M shares. You called it margin improvement on a shrinking base, and the market seems to have agreed. You also dropped the crowd-fade because 14 labeled posts is thin, then used the bearish headlines as contrarian fuel. That feed has titles only, no bodies, so it's the same grade of evidence.

On skew proving too much, nobody said zero. Skew changes the size, not the sign. A quarter to a third keeps the optionality. And a 20% loss needs a 25% gain to recover, so I don't weigh a missed squeeze the same as a realized gap.

Your re-entry rule bothers me most. You called Q1 margin improvement on a shrinking base, not demand recovery. Then you'd buy back on a print where the revenue decline merely narrows and gross margin holds near 42.8%. That's the same story you rejected, at a higher price. You told the neutral you can live with the lag of confirmation, so you can't hold the lag of a revenue-growth and positive-operating-cash-flow rule against me.

To the neutral analyst. You say sizing for a 20% gap treats a calendar risk as permanent. I accept that those gaps cluster around prints, but then apply it consistently. If you already know the number you want to hold into the print, there's no reason to wait until early December for the third tranche. The wait is a bet on a better price, the same fill-dependence you criticized in the aggressive's plan. Front-load, as the aggressive suggested. I'd do most of it now and finish by mid-November. What you'd give up by selling sooner is a squeeze to 42.88 or the 200 SMA near 46, which is 15% to 24% away, inside a weekly downtrend with the 50 SMA still falling.

The same calendar logic breaks your restore rule. Restoring half the trim on a weekly close above 38.77 puts you back above the number you computed as survivable, weeks before the print. If gap risk is a calendar risk, the time to lift the cap is after the print passes, not on a price signal ahead of it. The aggressive's version, cancelling unsold tranches on that signal, has the same flaw. A risk limit isn't a market view. I'd also be wary of OBV as a gate. The 406M it lost between 09-21 and 10-02 includes two days totaling about 255M shares, so much of that divergence is probably two event days, not a slow bleed.

On insiders, you said the dip to 32 fell in a blackout. But after the December 19 gap, directors and the CEO bought on December 22 and 29. After April 1, they bought April 7 through 13. Both clusters came within days of the print. This time the stock made a 52-week low, and if the print was around October 1, the window has probably been open two weeks or more at prices from 33 to 37. The insider feed, which runs through September 15, shows nothing. The feed could lag, so I'd want that confirmed. But it's the opposite of the pattern that made the insider buying a bull point.

On the missing 10-Q, consensus and tariff read, you both say they're fetchable and shouldn't break ties. Then fetch them. Until they're in hand, size to the lower number and let information raise it. Rebuilding size is reversible, and a gap isn't.

So I keep the Sell on NKE. Apply the formula with a 5% tolerance, which gives a quarter, unless the book can honestly absorb 8%. Treat 40% as a ceiling, not a target. Do most of the cut now, finish by mid-November, and cut the residual in half on a close below 34.47. Hold that budget through the print, then restore size on revenue growth and positive operating cash flow, or a weekly flip above 42.88. If you're flat, stay flat. Conservative Analyst: Most of what's left is small, so I'll say what I'm taking and then spend my time on four places I still disagree.

I'll take the third as the default. A third at the 15.5% gap we've actually seen costs about 5.2% of a standard allocation, which is what my quarter costs at a 20% stress. That fight is worth about a point of allocation. The input is the caller's loss tolerance divided by 0.20. I'd only go above 40% if the caller names that number, and since nobody proposed a tenth, I'll drop that one. I'm also glad the crowd-fade, the OBV gate, the insider silence and "defined-risk" are gone, and that the cap now holds through the print whatever price does.

First, the print date. It's a good catch, and I raised the same possibility, but it doesn't help the residual the way the aggressive says. If October 1 and 2 were the print, the best comparison in the dataset is already priced. The stock closed at 38.10 on September 8 and officers sold at 37.59 on September 9, before it. It's at 37.42 now. That's a round trip, not a re-rating. It also means the residual's catalyst isn't Q1. It's Q2, nine weeks out, which is the event the cap is sized for. And if those two days weren't the print, we have 255M shares of unexplained event volume in the last three weeks, which is a worse place to size from. It needs fetching either way, but neither answer argues for a bigger residual.

Second, speed. You both have half the trim now, the rest into 38.05 to 38.77 if offered, and a mid-November finish. The aggressive has told us he won't hang timing on the daily 9 and has thrown out OBV. So why wait for 38.05? It's a Bollinger band, and the technical report calls these reference levels, not validated resistance. If you're selling because the weekly and monthly trends are down and revenue is falling, you don't need a better price. The slice you're waiting on is also the one that stays exposed meanwhile. Waiting gains 1.7% to 3.6% on it if resistance holds, and costs 2% to 5% if the pullback you're selling for arrives. I'd sell about two-thirds of the trim now, give a limit at 38.05 a week to fill the last piece, and make early November the plan and mid-November the true backstop.

Third, the rebuild gates. Gross profit dollars is the right metric, and Q1 would have failed it, so that's progress. But the neutral's "gross margin holds near 42.8%" is a Q1 number, and the aggressive's own seasonal math puts Q2 near 41%. Written that way, the gate either never fires or gets quietly rewritten when the number lands, so write it year over year now. Positive free cash flow also won't discriminate. Nine-month FY26 FCF was $685M and Q1 was $15M, so Q2 and Q3 together made about $670M, while the dividend took about $1.2B over those two quarters. A quarter can clear that bar and still be funding the payout out of the $6.9B. Operating cash flow up year over year is the better test, since it fell 39% in Q1 and 62% over nine months. I'd also treat a weekly flip above 42.88 as a step to half, not full weight, because the monthly stop is still at 60.64.

Fourth, what's allowed to move the cap. The cap comes from the size of the gap, so only things that change the gap should move it: the caller's tolerance, the date of the next event, or a new event on the calendar. Insider buying doesn't. If the Form 4s since October 1 show directors buying, that supports the thesis, not a bigger cap. The record is sobering, too, because both prior clusters, December at 57 to 61 and April at 42 to 43, were followed by lower lows. So new information can lower the cap right away, but it should only raise it after the print.

The investor event works the same way. It's one StockTwits post with a Seeking Alpha link, not a calendar entry. If it's real, it's a date. An upside gap is what the residual is for, and a downside gap is what it's sized for.

One mechanical point. The 33.30 level is today's lower Bollinger band, and the band drifts with price. Pick a fixed price for the second cut so it can't move on you.

So my answer is still Sell. Size the residual at your loss tolerance divided by 0.20, defaulting to a third, a quarter if you can't absorb more, and half only if you name 10% yourself. Do about two-thirds of the trim now and finish by early November, with mid-November as the backstop. Hold the cap through the December print, cut it in half on a close below 34.47, and use a fixed price for the rest. Rebuild on year-over-year gross profit dollars and operating cash flow, and if you're flat, stay flat. Conservative Analyst: We're now close enough that most of what's left is cleanup, so I'll take what you've both landed and then spend my time on four places I'd still tighten.

On pace, I'm done arguing. You both now have two-thirds of the trim now when well over the cap, half when near it, one 38.05 limit that lives a week and then dies, and dates instead of prices. That's the plan I wanted. The aggressive is right that the slice we were fighting over is about a fifth of a standard position, so half-now near the cap is fine with me. I'll also take the aggressive's framing of the residual as a hedge against lag, sized by what you can afford to lose and not a bet that has to matter.

You're right about the ratchet. A rule that lets the cap fall on any news but rise only after the print is asymmetric in a way I can't defend cleanly. The cap should move with the caller's tolerance, the date of the next event, and the assumed gap size, in either direction, and nothing else. I never meant Form 4 silence to cut anything. The weekly flip above 42.88 in my last message was a post-print rebuild step, not a pre-print raise. Since both of you read it the other way, I'll say it plainly: every rebuild step happens after the print.

Now the four places I'd still push.

First, the gap-size input. You both want the October gap added to the count once it's fetched. I'd add one rule: it can raise the 20%, but it can't lower it. We have three known big gaps in ten months, the worst at 15.5%, and 20% is only about 1.3 times that. A mild October gap tells us one print was mild. The stress number is a ceiling with margin, not an average, and it shouldn't shrink because the latest sample was benign.

Second, the round trip. The aggressive now reads it as the market being neutral on the print, and the neutral says the October 1 and 2 move has mostly been walked back. Maybe. But about half of the 10.5% bounce came on one day, October 15, up 5.2% on 46.4M shares, and nobody here knows why. It could be a peer print, an upgrade, a rotation or a squeeze. If it was news, that isn't the market digesting the print. If it was a squeeze, a price barely above a still-falling 50 SMA is exactly what you'd sell into. So that day goes on the fetch list right behind the December date, ahead of the Form 4s.

Third, the rebuild gates, which are much better than before. The gross profit gate with $5.045B written down is a real test. On operating cash flow, though, the file's figures are cumulative, so a six-month comparison inherits Q1's $87M shortfall ($135M against $222M) before Q2 even starts. Test the standalone Q2 quarter, so the gate measures direction and not a hole already dug. On the ladder, one key to half of standard is fine. With both keys I'd stop at two-thirds and want a second print for full weight. The comps get easier from here, and Q3 FY26 was the trough at a 40.2% margin and $4.53B of gross profit. One clean year-over-year quarter partly reflects base effects, and the monthly stop is still at 60.64. That costs some participation if the turnaround is real. The intermediate step and the residual are what cover it.

Fourth, the deadline. The aggressive is right that the dividend declaration is a calendar date before the print. But the file lists $0.41 on December 1, March 2, June 1 and September 1 without saying whether those are ex-dates or payment dates. If they're payment dates, the declaration could land in the first half of November. Early November is the deadline that works under either reading, and mid-November stays the backstop. A cut is unlikely with $6.9B of cash, but it's the one scheduled event that can gap the stock before December.

So I keep the Sell. Size the residual at the caller's loss tolerance divided by 0.20, a third if they can't name a number, never more than half. Sell about two-thirds of the trim now if you're well over the cap, or half if you're near it, and finish by early November. The 38.05 limit gets one week. Hold the residual through the December print whatever price does. Halve it on a close below 34.47, and take the rest on a close below 31.97. Those are after-the-fact exits, and only the size protects you from a gap. Rebuild only after the print, in steps. If you're already under the cap, do nothing, and if you're flat, stay flat. Fetch the December date, what happened on October 15, the October gap, the dividend declaration date, the Form 4s, the 10-Q, consensus, the tariff read, and the investor event. None of that should hold up the first slice. Conservative Analyst: Most of this is settled, so I'll start with what I'm taking and then point to the soft spots left in the plan.

The neutral is right about the comparison, and I was wrong. I called Q2 an easy gross profit comp, but Q1's $4.80 billion plus the normal 2 to 2.5 percent step lands near $4.90 billion, so clearing $5.045 billion would take a real surprise. My base-effect worry belongs on Q3, where the trough is $4.53 billion, so full weight needing revenue growth is the right place for it. I also take the aggressive's point on small excess: if you're less than a tenth of standard over the cap, sell it and skip the limit order. And I'll take the stress number as a statistic, 1.3 times the worst gap in the sample, not a one-way valve.

First, the aggressive said a fetch showing he misread the quarter would cancel the remaining slice. That brings the ratchet back through the side door. We agreed the cap moves only with the caller's tolerance, the date of the next event, or the assumed gap size. The 10-Q, consensus, the tariff read and the Form 4s mostly describe a quarter the market has probably already traded, or an opinion about the next one. None of them changes when the gap lands or how big it can be. In practice this plan fails when a friendly-looking document shows up ten days before the deadline and talks someone out of the last slice. So write it down now. A fetch can speed up the selling or change the rebuild, but no fetch cancels a slice.

Second, the same discipline applies to the rebuild gates. The operating cash flow veto needs standalone Q2 from the 10-Q, and the base is already depressed, with nine-month operating cash flow down 62 percent. That makes "not down" a low bar, which is fine for a veto. But a veto you can't check shouldn't default to a pass. If the number isn't in hand, the key isn't met. The $5.045 billion gate works the same way. If the print comes in at $5.03 billion, the answer is no, and nobody gets to round it.

Third, I'd sharpen the aggressive's cost-of-being-wrong math. He set a hypothetical 10 percent upside gap against the 15.5 percent downside. The biggest upside gap we've seen is 4.9 percent, and at a third that misses about 3.3 points of a standard allocation. Against that, the downside we've actually seen avoids about 10 points. So the residual is cheaper than he made it sound, and that supports a third. His October observation, that the 32.55 open on October 2 was 9.8 percent below the September 21 close, probably adds another large down move to the count. I can't separate drift from gap without the September 30 close, so I won't count it yet. It is the direction the record keeps pointing.

Fourth, on the dividend, I have the same unverified recollection you two do, that the declaration comes in mid-November. If so, there is a dated event inside the next four weeks, which complicates the neutral's claim that gap risk is December. A cut is unlikely with $6.9 billion of cash. But the payout is about 100 percent of forward EPS and Q1 free cash flow was negative, so I don't see a comfortable outcome. A token raise deepens the burden, and a freeze would break a long streak if that recollection is right. That's a reason to be at the cap before the date, not after it. With a one-week limit on the 38.05 slice, the remainder sells around October 28 anyway. Early November becomes the backstop rather than the target, which is the right way round.

On the ladder, I won't fight any rung. The neutral is right that five rungs and nine fetches is more machinery than the evidence supports. What has to be written down before the first slice is the cap, the dates, the two fixed-price exits, and the rule that nothing gets rebuilt before the print.

So my answer is still Sell. Size the residual at your loss tolerance divided by 0.20, a third if you can't name a number, and never more than half. If you're well over that, sell about two-thirds of the excess now, or half if you're closer. Let the 38.05 limit live a week, then sell the rest at market. Hold the residual through the December print whatever price does, halve it on a close below 34.47, and take the rest on a close below 31.97. Those are after-the-fact exits, and only size protects you from a gap. If you're already at or under the cap, do nothing, and if you're flat, stay flat.

Neutral Analyst¶

Neutral Analyst: You two agree on the direction and are fighting over execution, and each of you is right about half of it.

Aggressive first. You called the residual half a defined-risk stake, and it isn't. The 34.47 level is a daily supertrend, a close-below trigger sitting 8.5% under price. This stock has printed a 10.5% gap and a 15.5% gap on over 100M shares, so a trigger like that tells you after you've been hurt. Only position size defines the risk, so I'd drop that phrase. You've also anchored the plan on a single fill at 38.05 when price is 37.42 and already inside your own sell zone. If the daily 9 does its job and this drifts back to the 10 EMA at 36.56, you waited for a price that never came. And I'd drop the crowd-fade as an edge. It's 14 labeled posts out of 15, from one afternoon, with Reddit off, and some unlabeled posts are planning to buy 36.50 to 36.90. The Sell stands on the weekly and monthly trends, the OBV divergence and the revenue decline without it. The insider point is also weaker than you made it. The dip to 32 happened around the print, when insiders are typically blacked out, so their silence there says little. Nobody buying through the summer window while a few officers sold is a fairer point, but it's small money.

Conservative, you're right about the stop and right that the re-entry rule needs to be set now. But sizing the residual to a 20% overnight gap today treats a calendar risk as permanent. Those gaps cluster around quarterly prints, and the next one is probably late December, about eight weeks out and unconfirmed. Between now and then, the realistic risk is a stock with a 2.8% ATR. If you drop to a quarter today, you give up most of the participation if this squeezes toward the 200 SMA near 46 or the weekly stop at 42.88. Four big-volume days, three down and one up, also isn't enough to call the skew fixed. The last cluster, October 1 and 2, ended with a bar that opened at 32.55, traded to 31.97 and closed 33.87 on 142.7M shares. That looks like a flush that buyers absorbed. I'm not calling it a bottom, just saying four data points don't settle the question. Your re-entry rule of revenue growth plus positive operating cash flow also has a cost. Those won't confirm until a print or two from now, and by then the stock has likely re-rated well above 39. As for your TD-9 symmetry point, the daily bar differs from the raw feed by a penny, while the monthly bar has about seven sessions left, so the daily 9 is less provisional. Still, I agree nobody should hang timing on either.

On cash flow, you're both leaning on Q1 FCF of -$64M. Q1 FY26 was +$15M, so the swing is $79M, and Q1 is seasonally the weak cash quarter. The real problem is nine-month FY26 FCF of $685M against $2.9B a year earlier. Financing outflows of about $600M a quarter look like the dividend alone, so buybacks are already gone. Even at zero FCF, $6.9B of cash covers a roughly $2.4B dividend for a couple of years. That's a reason not to hold a full position for the yield, but also not to treat a cut as imminent. On earnings, net income fell only $15M on $145M less gross profit, so something below the gross line, most plausibly cost cuts, offset nearly all of it. That's real but finite, and it's why I wouldn't sell down to zero.

You're also each using the missing 10-Q, consensus and tariff read to justify your own size. Those gaps can be closed before the last tranche, so they shouldn't be a tiebreaker.

So here is what I'd do. Keep the Sell, but split the trim into three pieces. Sell the first now around 37.4, just above the 50 SMA. Sell the second if it pushes into 38.05 to 38.77. Sell the third by early December regardless of price, sized to a number you can live with if the print gaps 20% against you. To get that number, divide the loss you can absorb, as a share of a standard position, by 0.20. A 5% loss tolerance gives you a quarter, and 8% gives you about 40%. That lands the endpoint between your two views and adapts to a book I can't see. If you're already below that number, don't sell more, and if you're flat, stay flat.

Treat 34.47 as a review level. A close below it puts all three timeframes down, so cut the residual by half. I wouldn't exit fully, because that level sits just above the 33.30 lower band and the 31.97 low where the last washout reversed.

Set re-entry now. Restore half of what you trimmed on a weekly close above 38.77 with OBV back above its 09-21 level of about -1.31B, which is a real divergence resolving, not a one-day uptick. Restore the rest after a print where the revenue decline narrows or reverses and gross margin holds near 42.8%.

That gets you the aggressive case for selling into strength and the conservative discipline on gap risk. It also avoids depending on one fill, one signal, or a stop that can't protect you. Neutral Analyst: We've narrowed this a lot, so I'll say where I'm moving, where I'm not, and what I think the fight is really about.

The conservative is right about my restore rule. Restoring half the trim on a weekly close above 38.77 would put you back over the survivable number weeks before the print, and gap risk doesn't care whether the daily trend is up. I'm dropping it. The OBV gate goes too. If two event days make up about 255M of the 406M OBV lost, then needing another 287M shares of net buying is a bar the stock may never clear before the next print, and it's a poor read of a slow bleed. That hits my rule and the aggressive's cancel-on-breakout rule, so before the print a breakout doesn't change the cap. The conservative is also right about the third tranche. A date in early December is a bet on a better price, so I'm moving the backstop to mid-November. And I'll concede the blackout point. If Oct 1 and 2 were the print, the insider window has been open for weeks. But the insider feed stops at September 15, so its silence says nothing about October either way. Pull the Form 4s since Oct 1 before anyone leans on insiders in either direction.

The aggressive is right to front-load. I'd sell about half the total trim now around 37.4, work the next piece into 38.05 to 38.77 if it's offered, and finish by mid-November at any price. The 38.05 entry in the trader's plan should be a target for one slice, not the plan.

Now the pushback. Conservative, a quarter sized for a 20% gap costs 5% of a standard allocation. A third at the worst gap we've actually seen, 15.5%, costs about 5.2%. So the difference between you is partly whether to stress beyond history. That's a fair choice, but it's a choice. Also, a standard position already carried these gaps. Cutting to a third removes two-thirds of that exposure, and going from a third to a quarter removes roughly another 1.3% of a standard allocation at a 15.5% gap. The aggressive's 3.7 points of allocation is right in that sense. The quarter-versus-third fight is worth about a percent either way. What matters is reaching the cap on time and not letting a price signal talk you out of it.

I'd also push back on "rebuilding is reversible." It's reversible, but it isn't free. Selling at 38 and rebuying at 42 is a real cost, and tax lots in a book I can't see could add to it. And on your restore rule, operating cash flow was already positive last quarter at $135M. What's broken is free cash flow after capex, against roughly $600M a quarter going out as dividends. A gate of "operating cash flow positive" is already met, so tie the rebuild to FCF turning positive. Finally, the Oct 1 and 2 reading is more ambiguous than you made it. Price is now 37.42 against 36.10 on 09-21, so whatever the market did on those days has been mostly walked back. That doesn't prove a bottom, but it doesn't prove the market rejected the improvement either.

Aggressive, "keep it big enough to matter" asks the residual to do more than the evidence supports. The option is a long way out of the money. It needs revenue to go from minus 4.3% to flat in one quarter. My claim that cost cuts explain the small net income decline is an inference, not something we've seen. You also dropped the crowd-fade for being thin, then used the bearish headlines as contrarian fuel, and the headlines are titles only, so that's the same grade of evidence. Your post-print rebuild rule is also too loose. A narrower revenue decline with margin holding is the margin-on-a-shrinking-base story you rejected, at a higher price. And a 50% residual only works if the caller's tolerance is 10%. That should be their number, not a default.

So here's where I land. Size the residual at the caller's loss tolerance divided by 0.20, capped at half of standard. If they can't name a number, use a third. If they're already below it, don't sell more, and if they're flat, stay flat. The cap holds through the print, and price action doesn't change it. Treat 34.47 as a review level, not protection. Cut the residual in half on a close below it and take the aggressive's version for the rest, which goes if the 33.30 band fails. By then the residual is small and all three timeframes agree.

After the print, rebuild in steps instead of with one cliff. Go to half of standard if the revenue decline narrows, gross margin holds near 42.8% and free cash flow turns positive. Go to full weight on revenue growth or a weekly flip above 42.88. That's less lag than the conservative's rule and more discipline than the aggressive's.

Last, you each used the missing data to support your own size, and I think the debate leans on one fetch more than any other. That's the date of the Q1 report and the stock's reaction to it. Whether Oct 1 and 2 were the print, whether insiders have been free to buy, and when the next gap risk lands all depend on it. Fetch that first, then the 10-Q, consensus and the tariff read, before the last tranche. Neutral Analyst: We're close enough that I'll skip the recap and say what I think each of you still has wrong, then give the version I'd hand the caller.

Aggressive, two things. First, the upside option is smaller than your tone suggests. Your flat-revenue case needs Q2 revenue to come in about 10.8% above Q1 sequentially. That step was 6.0% last year and 6.6% two years ago. Even your milder case, revenue down 1% to 1.5%, needs 9% to 10%. Run the normal seasonal step and revenue lands near minus 4% again, which is the trader's base case. That's rough arithmetic off two years of history, but it says the turnaround is a real tail, not a coin flip, and it's the best argument for a third over a half. Second, you called a possible October Form 4 cluster the strongest bullish fact in the file. Both earlier clusters, December at 57 to 61 and April at 42 to 43, were followed by prices all the way down to 31.97. A fresh cluster would tell you what directors think, not when they're right. It's worth reading, not worth resizing over. Taking the weekly flip above 42.88 straight to full weight is also the buy-high trap you warned about, since the monthly stop is still at 60.64.

Conservative, three things. Your cap rule is a ratchet. New information can lower it now but only raise it after the print. If silence in the Form 4s lowers the cap, you're resizing on a signal that doesn't change the gap, which is what you criticized in the crowd and OBV arguments. Only the caller's tolerance, the date of the next event and the assumed gap size should move the cap, in either direction. Everything else moves pace or rebuild.

On pace, two-thirds now sounds prudent, but look at what you're buying. If the caller goes from full to a third, the slice waiting at 38.05 is about a fifth of a standard position. A 3% price difference on that is under 1% of a standard allocation. The heavy-volume days in the file also sit on a quarterly rhythm (December 19, April 1, July 1, October 1 and 2), with the +5.2% on 10-15 the only other notable day. So the gap risk is the December print, about eight weeks out, not the next three weeks. I'd tie pace to how far over the cap the caller is. Far over, go closer to your two-thirds. Near it, half now is fine. Either way use dates, not prices, and let the 38.05 order live a week and then die.

On your operating-cash-flow gate, nine-month FY26 operating cash flow already fell 62%, so beating that base proves little alone. The six-month comparator also isn't in what we have, so it needs the 10-Q. It works as half a gate. And your step to half on a flip above 42.88 contradicts your own rule that nothing raises the cap before the print.

You're right that the 33.30 band drifts, and the same is true of 34.47, because a supertrend line tends to trail upward as price rises. Fix both. Cut half the residual on a close below 34.47. Take the rest on a close below 31.97, the October 2 low. The only reason to carry a residual is the idea that the flush was absorbed, and a close under that low says it wasn't.

For the rebuild, I'd use two keys, and only after the print. Key one is fundamentals: gross profit dollars up year over year and operating cash flow up year over year, with comparators from the filing. Key two is price: a weekly flip above 42.88. One key takes you to half of standard and both take you to full. That has less lag than waiting for revenue growth, and less buy-high risk than a price flip alone.

On the fetches, the event days fit quarter-end reporting and the Q1 FY27 statements are already in the file, so I'd treat that print as done. I can't see the size of the October gap, and it adds a data point to the skew count. Get the December date, that gap, the Form 4s, the 10-Q, consensus, the tariff read and any investor event. Also find when the next dividend declaration lands, since that decision may not wait for the print. None of this has to hold up the first slice, but the December date sets the deadline.

So the Sell stands, with the 38.05 level as one limit order and not the entry. Size the residual at the caller's loss tolerance divided by 0.20, a third if they can't name a number, never more than half. Reach it by early November, with mid-November as the backstop or a week before any earlier confirmed event. Hold it through the print whatever price does. If they're already under that size, do nothing, and if they're flat, stay flat. That keeps a real stake in the turnaround without letting one gap decide the outcome. Neutral Analyst: We've converged enough that the useful work left is to check the new pieces for cracks and hand the caller something short.

Conservative first. Your rule that the 20% stress can rise but never fall sounds like the ratchet you just gave up. It's fine if you state it as a statistic: the stress is 1.3 times the worst gap in the sample. A mild October gap then changes nothing, because the worst is still 15.5%, and a bigger gap raises it. That's a maximum, not a one-way valve, so I'll take it in that form.

I do disagree on the ladder. You want both keys to buy only two-thirds, with a second print for full weight, because comps get easier. That's true for Q3, where the gross profit trough is $4.53B. It isn't true for Q2. Q1 gross profit was $4.80B, and the normal Q1-to-Q2 step was 2.1% last year and 2.5% the year before. That lands near $4.90B to $4.92B. The $5.045B gate asks for $125M to $150M more than a normal quarter, about what Q1 gave up. A pass would be a real surprise, not a base effect. Your worry belongs on the second print. So I'll meet you: both keys gets two-thirds, and full weight needs year-over-year revenue growth, not another gross profit pass against an easy comp. That's your original demand in the right place.

On operating cash flow, standalone Q2 is the right test, but the file can't produce it. We have Q1 and nine-month figures but no six-month one, so Q2 FY26 on its own comes from the 10-Q. A single quarter also swings on inventory and payables timing, so I'd treat it as a veto on a close call, not a co-equal key. The fundamentals key is gross profit at or above $5.045B with operating cash flow not down year over year.

Aggressive, the round trip. You read 38.10 on September 8 against 37.42 today as proof the market was neutral on the print. That baseline sits three weeks before the event days. The last close we have before them is 36.10 on September 21, and against that the stock is up about 3.7%. That might still be roughly neutral, but we don't have the September 30 close, the October gap, or the reason for October 15, which supplied half the bounce. So neither "neutral" nor "rejected" should carry any weight in the plan. The Sell stands on trend and gross profit dollars, which is what you said you were relying on.

Something neither of you raised, and this is from memory, not the file. I believe Nike has raised its dividend every November for more than two decades, and the $0.41 dates in the file look like ex-dates, since I think payment comes about a month later. If so, the mid-November declaration is the annual decision: raise, freeze or cut. With $6.9B of cash I'd guess a token raise or a freeze before a cut, but that's a guess. You both framed this as cut risk, and it's a two-sided date where the cut is the tail. It doesn't change the cap. It does favor the conservative's early-November deadline over a mid-November target, since nobody has verified the date. Early November is the target, mid-November the backstop, and the declaration date goes on the fetch list.

To make the pace usable, define your terms. If the position is more than double the cap, sell about two-thirds of the excess now. If it's closer than that, sell half. The 38.05 order gets one week and then the remainder sells at market.

Here is what changes in the trader's plan. 38.05 stops being the entry and becomes one expiring limit. 34.47 is a review level, not protection. "Half of standard" gives way to a formula. The formula is the loss you can absorb divided by 0.20, a third if you can't name a number, never above half.

Hold that residual through the December print whatever price does. Halve it on a close below 34.47 and take the rest on a close below 31.97, the October 2 low. Those are after-the-fact exits, and only size protects you from a gap. Rebuild only after the print. The fundamentals key or a weekly flip above 42.88 gets you to half. Both get you to two-thirds. Full weight needs revenue growth.

Fetch the December date and the October gap first, then what happened on October 15, the dividend declaration date, the Form 4s since October 1, the 10-Q, consensus, the tariff read, and the investor event. None of it should hold up the first slice. If you're already under the cap, do nothing, and if you're flat, stay flat.

We now have a five-step ladder and nine fetches, which is more machinery than the evidence supports. The only part that matters over the next two weeks is getting to the cap by early November, and the rest can wait for the print. Neutral Analyst: We're close enough that I'll make three cleanups and two pushbacks, and then give the caller one short version.

First, my own cleanup. The pace rule I wrote last turn had three tiers: sell about two-thirds of the excess if you're far over the cap, half if you're closer, and everything if the excess is tiny. That's fiddlier than the evidence deserves. The whole fight was over a slice worth about a fifth of a standard position, and 3% on that is under a point of allocation. So here is one rule. Sell the excess now, except that up to a fifth of standard may sit on the 38.05 limit for one week. A full-weight holder with a third cap leaves about 20 points on the limit and sells roughly 47 now, which is about what two-thirds of the excess gave you. Anyone with an excess under a fifth sells it all today.

To the conservative: you're right that no fetch should cancel a slice, and the reason is stronger than you gave. Loss tolerance divided by 0.20 doesn't depend on the Sell thesis at all. It would apply to any stock that can gap 20%. The excess is excess whether or not a friendly article shows up, so consensus, tariff color, Form 4s and "turnaround" pieces can't touch it. I'd carve out one exception, because the file has a known reconciliation problem with the TTM figures and a missing Q4. If a filing shows the quarterly revenue or gross profit numbers we're relying on were wrong, that's a factual correction, and the plan should be re-run. Write that exception down now so it can't grow.

Your upside math is also inconsistent. For the stress you use 1.3 times the worst downside gap, which is 20%, but for the upside you use the sample maximum exactly, 4.9%. Apply the same treatment and the upside is about 6.4%. At two-thirds sold, that's roughly 4 points of standard allocation missed, against 10 to 13 points avoided. The conclusion survives, and a third is still right. But we shouldn't argue the sample is too small to fix the skew and then treat one upside observation as a ceiling.

On the dividend, I agree the date matters, and that's why the deadline sits before it. But I'd push back on "no comfortable outcome." A one-cent raise in the quarterly rate costs about $60M a year on a roughly $2.4B payout, which is immaterial against $6.9B of cash. The real tail is a cut, which I'd weight as unlikely. So the declaration is a reason to finish early. It isn't a second December.

To the aggressive: you're right that the excess stays exposed for every day of debate, and the single fifth-of-standard rule is the answer to that. I'd narrow your fetch rule, as above. A thesis check can't cancel a slice, but a factual correction can.

One fetch matters more than either of you has stressed. If management framed Q2 revenue on the Q1 call, as I believe it usually does, though I haven't verified it here, that's what tells you whether the $5.045B gross profit gate is realistic. If they guided to a mid-single-digit decline, the gate is a long shot and nobody should pencil a rebuild into their plan. That fetch changes expectations for the rebuild. It doesn't change the cap.

I agree with the conservative that an unverifiable key is not met. Standalone Q2 operating cash flow comes from the 10-Q, so if it isn't in hand, the rebuild waits. That costs days, not months, and the residual covers it.

The timeline now has too many dates. Under the one-week limit the plan is finished by October 28 in the base case. Early November only covers slippage, and mid-November is the hard backstop in case the dividend declaration lands earlier than anyone expects.

So the Sell stands, with these terms for the caller. Reduce to your loss tolerance divided by 0.20, a third if you can't name a number, never more than half. Sell the excess now, leaving at most a fifth of standard on a one-week limit at 38.05. Hold the residual through the December print whatever price does. Halve it on a close below 34.47 and take the rest on a close below 31.97. Those are after-the-fact exits, and only size protects you from a gap. Rebuild only after the print, and only on the gates already written down. If you're already at or under the cap, do nothing, and if you're flat, stay flat. The first slice doesn't wait for any fetch.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight NKE at 37.42: reduce exposure now, but do not exit. Cut to a residual equal to your tolerable loss (as a share of a standard position) divided by 0.20. That defaults to one-third of standard if you cannot name a number, and should never exceed half. Sell the excess immediately; at most a fifth of standard may rest on a single 38.05 limit for one week (to about Oct 28), after which it sells at market, with mid-November as the hard backstop ahead of the likely dividend declaration. If flat, do not initiate (no resting bid at 36.56); if already at or under the cap, do nothing. Hold the residual through the late-December Q2 print whatever price does: halve it on a daily close below 34.47, exit the rest on a close below 31.97 or on any dividend cut, and rebuild only after the print on pre-written gates.

Investment Thesis: Why the bear case wins. (1) Gross profit dollars are still falling: Q1 FY27 was $4.798B, down $145M YoY. Revenue growth decelerated from +1.1% to +0.6%, +0.1% and then -4.3%. The +60bps gross margin is margin on a shrinking base, not demand recovery. (2) The roughly $130M below-gross-profit saving that kept net income at -2% is unverified. Costs actually rose from 36.0% to 36.4% of revenue, and nobody has split the saving into overhead, marketing, tax or timing. (3) The Q2 base case is weak. A normal Q1-to-Q2 seasonal step (+2.1% to +2.5%) puts gross profit near $4.90-4.92B, about -3% YoY. Flat revenue would need a +10.8% sequential step, against +6.0% and +6.6% in the past two years. On the debate's probabilities (about 23% pass, 49% status quo, 28% fail), expected Q2 EPS is roughly $0.43-0.52 against a $0.57 pass bar. (4) Valuation is not distressed. The stock trades at 23.4x forward EPS of $1.60, below TTM EPS of $2.08, and the 18x TTM P/E is unreliable because TTM does not reconcile with the quarterly data. (5) The dividend is at risk. It is covered about 0.98x by forward EPS, Q1 FCF was -$64M, cash fell $660M in the quarter, buybacks appear halted, and a new CFO started 9/1. (6) The tape is a roughly 10% counter-trend bounce. The weekly supertrend is down (stop 42.88) and the monthly is down (stop 60.64). Price sits just above a still-falling 50 SMA (37.18), 1.7% below the upper band (38.05) and 3.6% below the 38.77 September high, with lower monthly closing highs every month since January. (7) Gap history is skewed to the downside: -10.5% and -15.5% versus +4.9%. The October 2 open at 32.55 was 9.8% below the 9/21 close, which suggests another large down move. Why not Sell: the balance sheet is sound ($6.9B cash, 2.08 current ratio, net debt about 0.9x EBITDA). Like-for-like margins and costs show real improvement. The October 2 flush (low 31.97, close 33.87 on 142.7M shares) was absorbed, and there is a roughly 23% chance the bull's Q2 case passes, so a full exit gives up a credible tail. Why not Hold: the evidence is not balanced, since about 77% of the probability mass sits in outcomes where neither side would own the stock. Sizing logic from the risk debate, which refines the Research Manager's 50%: the 34.47 daily supertrend is a close-below trigger 8% away on a stock that gaps 10-15%, so only size limits loss. A half position hit by a 15% gap costs 7.5% of a standard allocation; a third hit by the worst observed 15.5% gap costs about 5.2%; a third under a 20% stress (1.3x the worst gap) costs about 6.7%. Selling two-thirds forgoes only about 4 points of standard allocation on a stressed upside gap of about 6.4%. Pace follows dates, not prices, because the daily TD-9 and OBV readings are unreliable: today's bar may still be forming, and two event days explain most of the OBV divergence. The trader's 38.05 entry becomes one expiring limit, not the plan. The cap moves only with your tolerance, the date of the next event, or the assumed gap size. New information can accelerate selling but cannot cancel a slice. The one exception is a filing showing the quarterly revenue or gross profit figures relied on here were wrong, in which case the plan should be re-run. Exit the residual early on any of: a dividend cut, the 10-Q showing the saving was mainly marketing or non-recurring, or Q2 gross profit at -3% or worse with EPS below about $0.45. A status-quo print (gross profit about -3%, EPS $0.50-0.52, dividend at $0.41) means keep the underweight with no adds. Rebuild only after the print, using two keys. The fundamentals key requires Q2 gross profit of at least $5.045B (no rounding) and standalone Q2 operating cash flow not down YoY, verified from the 10-Q; unverified counts as not met. The price key is a weekly close above 42.88. One key takes you to half of standard, both to two-thirds, and full weight additionally requires YoY revenue growth with the dividend held. Fetch list, none of which delays the first slice: the confirmed Q2 date and the size of the October gap; the cause of the +5.2% move on Oct 15; the dividend declaration date (likely mid-November, unverified); the 10-Q and Q1 call (cost split, Q2 revenue guide, region and channel detail, tariff exposure in Vietnam, Indonesia and China); consensus; Form 4s since Oct 1; and the rumored investor event. Price target method, a valuation objective: forward EPS of $1.60 times 21x equals $33.60. The 21x multiple is a roughly 10% de-rating from the current 23.4x, about midway toward the 19.4x Q1 run-rate multiple cited by the Research Manager. That reflects the status-quo and fail outcomes that dominate the probability mass, where falling gross profit dollars and about 100% forward payout should not sustain a growth-like multiple. Cross-check: $33.60 sits between the 33.30 lower Bollinger band and the 34.47 daily supertrend, about 10% below the close, consistent with the size of prior post-print moves. Confidence is medium on direction and sizing but low on the target itself. Data gaps include the missing 10-Q, consensus and Q4 FY26, a non-reconciling TTM, and a possibly forming bar with a $0.01 feed discrepancy (37.41 vs 37.42).

Current Price: 37.42

Price Target: 33.6

Confidence: Medium

Time Horizon: 2-3 months

Trading Analysis Report: NKE¶

I. Analyst Team Reports¶

Market Analyst¶

NKE (NIKE, Inc., NYSE): technical report¶

Indicators chosen (8) and why¶

1. Big picture: a persistent downtrend¶

2. Multi-timeframe trend (supertrend, weekly > monthly > daily)¶

3. The rebound since the 10-02 low¶

4. Momentum¶

5. Volume (OBV)¶

6. Exhaustion and stretch¶

7. Volatility and risk sizing¶

8. Scenario map (reference levels from indicators, not validated support or resistance)¶

Summary table¶

Sentiment Analyst¶

News Analyst¶

NKE (NIKE, Inc.) – News and Macro Report, week of 2026-10-14 to 2026-10-21¶

1. Data coverage and limits¶

2. Company news for NKE¶

3. Macro and market backdrop¶

4. Trading takeaways¶

5. Summary table¶

Fundamentals Analyst¶

NKE (NIKE, Inc.) Fundamental Report, as of 2026-10-21¶

1. Company Profile and Snapshot¶

2. Income Statement Trends (quarterly, USD millions)¶

3. Balance Sheet (USD millions)¶

4. Cash Flow (cash flow figures are year-to-date cumulative; USD millions)¶

5. Insider Activity¶

6. Actionable Observations (for the decision-maker)¶

7. Data Quality Caveats¶

8. Summary Table¶

II. Research Team Decision¶

Bull Researcher¶

1. The earnings decline has nearly stopped¶

2. The balance sheet buys time¶

3. The valuation embeds a lot of pessimism¶

4. Insiders put real money in, including the CEO¶

5. The tape shows capitulation, then a turn¶

Where I expect the bear to push, and my answers¶

Macro and what I can't verify¶

Bottom line¶

What I concede¶

Your seasonality correction helps me¶

The gross-profit math is right, but the conclusion isn't¶

Revenue: you're right¶

The dividend: uncovered by FCF, but less alarming than framed¶

Valuation: use quarterly data¶

The tape¶

Sequencing: where I move toward you¶

Revised checklist (replaces mine)¶

Your question, answered¶

What I concede¶

The "hole" is narrower than "unknown"¶

The checklist, rebuilt around gross profit dollars¶

Street math¶

The tape¶

Revised sequence¶

Where we still differ¶

What I concede¶

Where the bear overreaches¶

1. "The cost reset earns nothing" is true only at the status quo¶

2. The confirmation triggers charge a second toll¶

The plan, with the starter fixed¶

Where we stand¶

Final stance¶

What I concede¶

Where I still push back¶

1. "Twice the seasonal step" can be two small deviations¶

2. Waiting isn't free, but it still wins¶

3. What the stock costs if a pass happens¶

4. The dividend cliff isn't near, though the coverage is thin¶

The revised starter¶

Final plan¶

Where we land¶

Bear Researcher¶

1. "−30% to −2%" is a base effect, and gross profit dollars fell¶

2. Your margin table mixes seasons¶

3. Adidas's record quarter is a share-loss argument¶

4. The dividend is the last lever left¶